var title_f14_56_15232="Post fossa ependymoma MRI Gad";
var content_f14_56_15232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior fossa ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1 weighted axial MR image demonstrating a posterior fossa lesion that enhances with gadolinium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Kieran, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15232=[""].join("\n");
var outline_f14_56_15232=null;
var title_f14_56_15233="Bromperidol: International drug information";
var content_f14_56_15233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bromperidol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bromidol (DK);",
"     </li>",
"     <li>",
"      Bromidol Depot (DK);",
"     </li>",
"     <li>",
"      Bromodol (AR);",
"     </li>",
"     <li>",
"      Bromodol Decanoato (AR);",
"     </li>",
"     <li>",
"      Erodium (AR);",
"     </li>",
"     <li>",
"      Impromen (BE, DE, IT, LU, NL);",
"     </li>",
"     <li>",
"      Impromen decanoas (BE, LU, NL);",
"     </li>",
"     <li>",
"      Impromen Tropfen (DE);",
"     </li>",
"     <li>",
"      Tesoprel (DE);",
"     </li>",
"     <li>",
"      Tesoprel Tropfen (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Bromperidol Decanoate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Typical, Phenothiazine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia and other psychoses",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 1-15 mg/day, up to 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: 300 mg every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, solution, as decanoate: 50 mg/mL (1 mL, 3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, oral: 30 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 5 mg, 10 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10346 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15233=[""].join("\n");
var outline_f14_56_15233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303340\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978036\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978038\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978041\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978037\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821185\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978040\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15234="Chest x-ray - tropical pulmonary eosinophilia";
var content_f14_56_15234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Chest x-ray - tropical pulmonary eosinophilia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Chest x-ray of young Indian male presenting with symptoms suggestive of asthma.",
"    <br>",
"     (B) Follow-up chest x-ray two weeks after diethylcarbazine therapy for suspected tropical pulmonary eosinophilia demonstrates improvement in subtle chest x-ray findings.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Peter Weller, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15234=[""].join("\n");
var outline_f14_56_15234=null;
var title_f14_56_15235="Scintigraphy hydrothorax";
var content_f14_56_15235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Abdominal and thoracic scintigraphy demonstrating hydrothorax in a peritoneal dialysis patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) At 30 min no thoracic activity is noted. At 4 hr (B) there is focal accumulation of activity at the level of dome of right diaphragm as well as less intense focus just above the level of the right diaphragm medially (arrows). Imaging at 20 hr (C) post dialysate exchange reveals further accumulation of activity medially just above the right diaphragm as well as a slight degree of diffuse activity on the right hemithorax (arrows), d (diaphragm).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walker JV, Fish MB. Scintigraphic detection of abdominal wall and diaphragmatic peritoneal leaks in patients on continuous ambulatory peritoneal dialysis. J Nucl Med 1988; 29:1596. Copyright &copy; 1988 Society of Nuclear Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15235=[""].join("\n");
var outline_f14_56_15235=null;
var title_f14_56_15236="Anal sphincter anatomy PI";
var content_f14_56_15236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Anal sphincter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anal sphincter is made up of two sets of muscles called the \"internal\" and \"external\" sphincters. These muscles form a ring around the anus. When these muscles are working normally, they squeeze the anus shut so that gas and bowel movements cannot leak out.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15236=[""].join("\n");
var outline_f14_56_15236=null;
var title_f14_56_15237="Airway in a person with sleep apnea PI";
var content_f14_56_15237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Airway in a person with sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 624px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normally when a person sleeps, the airway remains open, and air can pass from the nose and mouth to the lungs. In a person with sleep apnea, parts of the throat and mouth drop into the airway and block off the flow of air. This can cause loud snoring and interrupt breathing for short periods.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15237=[""].join("\n");
var outline_f14_56_15237=null;
var title_f14_56_15238="Management of patients with prosthetic heart valves";
var content_f14_56_15238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of patients with prosthetic heart valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Gerard P Aurigemma, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15238/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15238/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/56/15238/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo cardiac valve replacement, approximately 60 percent receive mechanical valves composed of carbon alloys with a tilting disk or bileaflet design. The remaining 40 percent receive bioprosthetic valves, which may be heterografts, composed of porcine or bovine tissue, homografts, which are preserved human aortic valves, or pulmonary autografts.",
"   </p>",
"   <p>",
"    Replacement of a diseased heart valve with a prosthetic valve exchanges the native disease for complications that are peculiar to the prosthesis. The frequency of serious complications depends upon the valve type and position, and multiple other clinical risk factors.",
"   </p>",
"   <p>",
"    Thromboembolic and anticoagulation-related problems are the most frequent complications of mechanical valves. In contrast, structural failure is relatively rare with these prostheses compared to bioprosthetic valves. Other major complications of prosthetic heart valves include endocarditis, paravalvular leak, and hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are five main issues for managing and advising the patient with a prosthetic heart valve:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antithrombotic therapy to prevent valve thrombosis and thromboembolism",
"     </li>",
"     <li>",
"      Evaluation of valve function",
"     </li>",
"     <li>",
"      Endocarditis prophylaxis",
"     </li>",
"     <li>",
"      Safety of exercise",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other vitamin K antagonist)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is recommended in patients with prosthetic heart valves to prevent valve thrombosis and thromboembolic events. Recommendations for therapy vary with the type of valve (the risk is much greater with mechanical valves), the site of valve replacement (the risk is greater with mitral than aortic valves), the presence or absence of underlying risk factors for thrombus formation, and certain clinical settings, such as pregnancy and surgical procedures. The benefits of anticoagulation therapy must be weighed against the risk of bleeding, particularly intracranial bleeding.",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SERIAL MONITORING OF VALVE FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of late structural failure varies among the different types of prosthetic heart valves. Most current mechanical valves can be expected to last 20 to 30 years or more. In contrast, 10 to 20 percent of human aortic homograft prostheses, and 30 to 35 percent of porcine heterograft prostheses fail within 10 to 15 years of implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The failure rate with porcine valves is higher with mitral compared to aortic valves (eg, 36 versus 15 percent at 11 years in the Veterans Administration Cooperative Study) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valve function is typically assessed by history, physical examination, and echocardiography. We agree with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease, which recommended the following approach to follow-up evaluation after prosthetic valve implantation (",
"    <a class=\"graphic graphic_table graphicRef63090 \" href=\"UTD.htm?5/54/5996\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first outpatient visit at two to four weeks after hospital discharge is aimed at assessing function of the prosthetic valve and looking for signs of infection, conduction disturbance, or myocardial infarction. The evaluation should include an interval history, physical examination, electrocardiogram, chest x-ray, appropriate blood tests (complete blood count, creatinine, electrolytes, lactate dehydrogenase, and INR if indicated). If not obtained before discharge, a baseline transthoracic Doppler echocardiogram should be obtained.",
"     </li>",
"     <li>",
"      Routine follow-up visits in asymptomatic patients should occur yearly. The evaluation should include a complete history and physical examination; other tests are performed as indicated.",
"     </li>",
"     <li>",
"      In asymptomatic patients without evidence of left ventricular or valve dysfunction, routine annual echocardiography is",
"      <strong>",
"       not",
"      </strong>",
"      indicated in patients with mechanical valves or during the first five years with bioprosthetic valves. The evidence was considered less well established for routine annual echocardiography after the first five years in patients with bioprosthetic valves which, as noted above, have a failure rate as high as 30 percent within 10 to 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Repeat evaluation with echocardiography should be performed any time there is a change in clinical status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performing a history and physical examination in patients with prosthetic heart valve, particular attention should be given to the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subtle symptoms of heart failure or neurologic events can be clues to serious valve dysfunction. The physical findings may confirm embolic events suggested from the history.",
"     </li>",
"     <li>",
"      Abnormal auscultatory findings, which vary with the type of valve that has been inserted, may be suggestive of valvular abnormalities (",
"      <a class=\"graphic graphic_table graphicRef61951 graphicRef70856 \" href=\"UTD.htm?21/23/21885\">",
"       table 2A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/1\">",
"       1",
"      </a>",
"      ]. As an example, absence of the typical opening and closing sounds may be suggestive of valve thrombosis, while development of a new murmur may indicate prosthetic valve dysfunction or a paravalvular leak. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Echo-Doppler studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus concerning the optimal frequency of echo-Doppler studies in patients with prosthetic heart valves. We perform a baseline study in all patients at the time of hospital discharge or at their first postoperative follow-up visit. This study is used to document the stability of the valve, the presence and extent of valvular or paravalvular regurgitation, and the transvalvular pressure gradients.",
"   </p>",
"   <p>",
"    Transthoracic echocardiography is generally used for the baseline study, although transesophageal echocardiography (TEE) may be indicated in selected patients (eg, those with a suspected paravalvular leak from a mitral prosthesis or patients with a suspected cardiac source of embolism) (",
"    <a class=\"graphic graphic_movie graphicRef67281 \" href=\"UTD.htm?18/13/18655\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef68507 \" href=\"UTD.htm?34/29/35282\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef75409 \" href=\"UTD.htm?41/29/42449\">",
"     movie 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=see_link\">",
"     \"Echocardiographic evaluation of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Doppler-derived velocities have been used to evaluate the function of prosthetic valves. One study, for example, found that application of the continuity equation and calculation of valve resistance provided a reliable method to distinguish whether a high velocity and gradient across a St. Jude aortic valve was secondary to obstruction or increased flow (as with paravalvular aortic regurgitation) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/10\">",
"     10",
"    </a>",
"    ]. Parameters that differentiated stenotic from regurgitant and normal valves were effective orifice area, Doppler velocity index, and valve resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since valve degeneration is a concern with bioprosthetic valves, it would seem reasonable to repeat the echocardiographic study in such patients after three to five years. Subsequent studies are performed at increasing frequency thereafter, depending upon the clinical circumstances. Given the durability and relatively infrequent complications of the newer generation mechanical valves, follow-up studies may safely be performed at relatively long intervals, perhaps every five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of prosthetic heart valves\", section on 'Mechanical versus bioprosthetic valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to routine monitoring of patients with prosthetic heart valves, periodic echocardiography frequently is indicated for residual cardiac abnormalities, such as left ventricular dilation or systolic dysfunction, abnormalities of other valves, and persistent pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other studies are rarely indicated in healthy patients with prosthetic heart valves. ECG and chest x-ray are not performed on a routine basis in the absence of a specific indication. Cinefluoroscopy can be used to assess disk and poppet motion in mechanical valves, especially in patients who have shown an auscultatory change. The serum lactate dehydrogenase concentration is frequently mildly elevated due to hemolysis resulting from trauma induced by the prosthetic valve. However, hemolysis severe enough to produce anemia is unusual with the newer generation prosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of antibiotic prophylaxis was illustrated in a study of 533 patients with prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/11\">",
"     11",
"    </a>",
"    ]. Antibiotics were administered to 304 patients prior to undergoing invasive procedures thought to be capable of causing bacteremia with organisms known or likely to cause endocarditis, while 229 similar patients did not receive antimicrobial therapy. Endocarditis developed in 6 of the 229 (2.7 percent) untreated patients versus none of the 304 treated patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with prosthetic heart valves are at high risk for endocarditis and should use prophylactic antibiotics in accordance with current guidelines (",
"    <a class=\"graphic graphic_table graphicRef57182 \" href=\"UTD.htm?39/63/40956\">",
"     table 3",
"    </a>",
"    ). The recommended regimens are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased cardiac output that occurs during exercise produces increased transvalvular pressure gradients that are of uncertain clinical significance. In addition, data are limited about the effects of vigorous exercise on prosthetic valve function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regular moderate exercise to maintain cardiovascular fitness is encouraged. Issues related to participation in competitive sports were addressed by the 36th Bethesda Conference; the recommendations vary with the type and location of the prosthetic heart valve and the intensity and type of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15238/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a bioprosthetic mitral valve who have normal valve function, normal or near-normal left ventricular function, and are not being treated with anticoagulation can participate in low and moderate static and dynamic competitive sports (class IA, IB, IIA, and IIB) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a mechanical or bioprosthetic aortic valve who have normal valve and left ventricular function can participate in low and moderate static and low and moderate dynamic competitive sports (class IA, IB, and IIA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients participating in more than low-intensity sports (class IA) should undergo exercise testing to at least the level of activity attained in competition to evaluate both exercise tolerance and symptom and hemodynamic responses.",
"     </li>",
"     <li>",
"      Independent of the above considerations, patients treated with anticoagulation should not participate in sports associated with the risk of bodily contact or the danger of trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in women with prosthetic heart valves is complicated by the need for antithrombotic therapy to prevent valve thrombosis and thromboembolism.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    exposure between the sixth and twelfth week of gestation can cause a specific embryopathy affecting cartilage and bone. Warfarin embryopathy has an estimated incidence of 5 to 7 percent, although reported ranges vary and appear to correlate with the dose.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    does not cause embryopathy but is associated with a higher risk of valve thrombosis.",
"   </p>",
"   <p>",
"    The optimal approach to such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       \"Patient information: Prosthetic valves (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13876774\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main issues for managing and advising a patient with a prosthetic heart valve are management of antithrombotic therapy, evaluation of valve function, endocarditis prophylaxis, safety of exercise, and pregnancy.",
"     </li>",
"     <li>",
"      Antithrombotic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (or other vitamin K antagonist)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is recommended in patients with prosthetic heart valves to prevent valve thrombosis and thromboembolic events. Recommendations for therapy vary with the type of valve (the risk is much greater with mechanical valves), the site of valve replacement (the risk is greater with mitral than aortic valves), the presence or absence of underlying risk factors for thrombus formation, and certain clinical settings, such as pregnancy and surgical procedures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all patients receiving a prosthetic heart valve, a baseline echocardiogram is suggested at the time of hospital discharge or at their first postoperative follow-up visit two to four weeks after discharge. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serial monitoring of valve function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients without evidence of left ventricular or valve dysfunction, routine annual echocardiography is",
"      <strong>",
"       not",
"      </strong>",
"      indicated in patients with mechanical valves or during the first five years with bioprosthetic valves. Repeat evaluation with echocardiography should be performed any time there is a change in clinical status. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serial monitoring of valve function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with prosthetic heart valves are at high risk for endocarditis and should use prophylactic antibiotics in accordance with current guidelines (",
"      <a class=\"graphic graphic_table graphicRef57182 \" href=\"UTD.htm?39/63/40956\">",
"       table 3",
"      </a>",
"      ). The recommended regimens are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regular moderate exercise to maintain cardiovascular fitness is encouraged in patients with prosthetic valves. Recommendations for competitive sports vary with the site and type of valve. All patients treated with anticoagulation should not participate in sports associated with risk of bodily contact or danger of trauma. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy in women with prosthetic heart valves is complicated by the need for antithrombotic therapy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      exposure poses a risk of embryopathy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      does not cause embryopathy but is associated with a higher risk of valve thrombosis. The optimal approach to such patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"       \"Management of pregnant women with prosthetic heart valves\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/1\">",
"      Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/2\">",
"      Yacoub M, Rasmi NR, Sundt TM, et al. Fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg 1995; 110:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/3\">",
"      O'Brien MF, Stafford EG, Gardner MA, et al. Allograft aortic valve replacement: long-term follow-up. Ann Thorac Surg 1995; 60:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/4\">",
"      Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/5\">",
"      Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/6\">",
"      Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991; 324:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/7\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/8\">",
"      Olmos L, Salazar G, Barbetseas J, et al. Usefulness of transthoracic echocardiography in detecting significant prosthetic mitral valve regurgitation. Am J Cardiol 1999; 83:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/9\">",
"      Shiran A, Weissman NJ, Merdler A, et al. Transesophageal echocardiographic findings in patients with nonobstructed prosthetic valves and suspected cardiac source of embolism. Am J Cardiol 2001; 88:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/10\">",
"      Saad RM, Barbetseas J, Olmos L, et al. Application of the continuity equation and valve resistance to the evaluation of St. Jude Medical prosthetic aortic valve dysfunction. Am J Cardiol 1997; 80:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/11\">",
"      Horstkotte D, Friedrichs W, Pippert H, et al. [Benefits of endocarditis prevention in patients with prosthetic heart valves]. Z Kardiol 1986; 75:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/12\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15238/abstract/13\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8134 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15238=[""].join("\n");
var outline_f14_56_15238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SERIAL MONITORING OF VALVE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Echo-Doppler studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13876774\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8134|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8134|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/13/18655\" title=\"movie 1\">",
"      Aortic valve bioprosthesis short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/29/35282\" title=\"movie 2\">",
"      Aortic valve homograft transesophageal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/29/42449\" title=\"movie 3\">",
"      Prosthetic mitral valve four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/54/5996\" title=\"table 1\">",
"      Followup prosthetic heart valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/14/31980\" title=\"table 2A\">",
"      Normal ausculatory findings of prosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/59/36795\" title=\"table 2B\">",
"      Abnl findings prosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/63/40956\" title=\"table 3\">",
"      Antibiotic regimens dental",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=related_link\">",
"      Echocardiographic evaluation of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15239="Beta-2 adrenergic receptor dysfunction and polymorphism in asthma";
var content_f14_56_15239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Ian P Hall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15239/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/56/15239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the powerful bronchodilatory properties of beta adrenergic agonists have been appreciated for many years, understanding of the molecular basis of their activity at the beta-2 adrenergic receptor did not begin until the late 1980s. The mechanisms of signal transduction from this receptor and the potential role of beta-2 adrenergic receptor dysfunction in the pathogenesis of asthma and its response to therapy will be reviewed here. The clinical use of beta agonists in the treatment of asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL RECEPTOR REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene encoding the beta-2 adrenergic receptor is situated on chromosome 5q31 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/1\">",
"     1",
"    </a>",
"    ]. It encodes a protein that is a member of the large family of G-protein coupled, seven transmembrane-spanning domain receptors. The receptor is expressed on a variety of cell types in the lung, including airway smooth muscle and epithelial cells, vascular endothelium and smooth muscle cells, and inflammatory cells such as mast cells, eosinophils, and lymphocytes.",
"   </p>",
"   <p>",
"    Stimulation of the beta-2 receptor results in activation of the associated G-protein, Gs, which dissociates to release a protein subunit, free Gs-alpha. Gs-alpha in turn activates adenylyl cyclase, resulting in a rise in intracellular cyclic AMP levels. Most of the intracellular effects of beta-2 adrenergic receptor stimulation are due to the elevation in cyclic AMP and consequent activation of protein kinase A (PKA); there may also be direct, cyclic AMP-independent effects of Gs-alpha on the calcium-activated potassium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=see_link&amp;anchor=H3#H3\">",
"     \"Peptide hormone signal transduction and regulation\", section on 'G proteins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The expression of beta-2 adrenergic receptors and their coupling with intracellular signaling pathways are dynamically regulated, providing a negative feedback loop that reduces cell responsiveness to long-term occupation of the receptor by an agonist. Phosphorylation of the receptor, either by PKA-dependent pathways or by activation of one of a family of G-protein receptor kinases termed beta-ARKs, leads to reduced coupling with the intracellular signaling pathway following agonist stimulation. Different tissues vary in the degree of uncoupling seen with prolonged agonist exposure, probably due to differences in the amount and activity of beta-ARK",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PKA in different cell types.",
"   </p>",
"   <p>",
"    The number of receptors also is actively regulated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta-2 receptor number is reduced after exposure to agonist for more than two hours",
"     </li>",
"     <li>",
"      Beta-2 adrenoceptor expression in airway cells is downregulated after exposure to viruses or to pro-inflammatory cytokines, such as interleukin 1-beta [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Beta-2 receptor number is increased by in vitro exposure to glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RECEPTOR DYSFUNCTION IN ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that medication-induced changes in beta receptor density or signal transduction impact detrimentally upon asthma control has been repeatedly suggested in the literature, although supporting evidence has been scant. Beta-2 adrenergic receptor dysfunction has been documented in in vitro studies of tissue obtained from patients with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]; however, clinically significant tachyphylaxis to the bronchodilator effects of beta-2 agonists has been difficult to demonstrate in patients with mild asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large number of studies have examined the effect of scheduled treatment with short-acting beta-2 agonists on asthma control [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/12-20\">",
"     12-20",
"    </a>",
"    ]. The majority of these reports found NO significant deterioration in symptoms, lung function, or the need for rescue medications. Several studies demonstrated a small deterioration in symptom score, FEV",
"    <sub>",
"     1",
"    </sub>",
"    , or response to bronchoprovocation when beta agonists were used regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/2,12,20\">",
"     2,12,20",
"    </a>",
"    ], and rebound hyperresponsiveness has been noted following beta agonist withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/21\">",
"     21",
"    </a>",
"    ]. While more intense beta agonist use does not have a large detrimental effect, regular treatment with a short-acting beta-agonist appears to confer no advantage over \"as required\" use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECEPTOR POLYMORPHISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of polymorphic forms of the beta-2 adrenergic receptor were described in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/22\">",
"     22",
"    </a>",
"    ]. These polymorphisms appear to be in linkage disequilibrium in the Caucasian population. Each individual has two genes for the beta-2 adrenergic receptor and hence can be heterozygous or homozygous for each polymorphism.",
"   </p>",
"   <p>",
"    Nine point mutations have been found within the beta-2 adrenergic receptor gene, although only four result in amino acid substitutions because of redundancy in the amino acid translation code.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arginine to glycine 16 and glutamine to glutamate 27 substitutions are common in the Caucasian population; allele frequencies at each locus are between 0.3 and 0.7 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/23\">",
"       23",
"      </a>",
"      ]. In an in vitro study, homozygosity of Gly 16 resulted in greater downregulation (96 percent) and homozygosity of Glu 27 in less downregulation (29 percent) of the beta-2 receptor in response to agonists than occurred with the wild type (78 percent), although agonist binding kinetics were not affected [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/24\">",
"       24",
"      </a>",
"      ]. Both the codon 16 and codon 27 polymorphisms are in Hardy-Weinberg equilibrium in the general population. However, there is linkage disequilibrium between the two loci, with individuals who have glycine 16 being more likely (in the Caucasian population) to have glutamate 27 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The threonine to isoleucine 164 mutation is rare (allelic frequency 3 percent), but produces marked alterations in the in vitro behavior of the receptor. Cells transfected with this form of the receptor display reduced agonist binding to catechol ligands and have altered receptor trafficking [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/27\">",
"       27",
"      </a>",
"      ]. This polymorphism is also close to the putative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      exosite. Data from a large population based study, the Copenhagen City Heart Study, found an association between this polymorphism and the presence of airflow limitation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/28\">",
"       28",
"      </a>",
"      ]. However, few individuals homozygous for this polymorphism have been identified, and therefore its physiologic effects on airway responses are uncertain.",
"     </li>",
"     <li>",
"      The valine to methionine 34 substitution is rare and does not appear to alter receptor function.",
"     </li>",
"     <li>",
"      The regulatory region (promoter) for the beta-2 adrenergic receptor gene also contains functionally relevant polymorphisms; the clinical importance of this remains to be fully determined [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. The possibility that combinations of these polymorphisms are deleterious is also worthy of further study, although functional data are currently limited on haplotype driven effects [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that beta-2 adrenergic receptor polymorphism may alter the response to treatment or influence susceptibility to asthma has been investigated in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/25,26,33-44\">",
"     25,26,33-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment response to regular SABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not consistent across all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/36\">",
"     36",
"    </a>",
"    ], several studies have found that frequent or regularly scheduled short-acting beta-agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) impaired asthma control in patients who were homozygous for arginine at the 16th amino acid position (ie, Arg16Arg) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/34,41,42,45\">",
"     34,41,42,45",
"    </a>",
"    ]. This was best illustrated by a prospective, blinded study of 78 patients with mild asthma who were treated with regularly scheduled albuterol or placebo for eight weeks, then crossed over to the other treatment for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with the Arg16Arg genotype experienced a decrease in morning peak expiratory flow rate (PEFR) (-10",
"    <span class=\"nowrap\">",
"     L/m",
"    </span>",
"    compared to placebo), while patients with the Gly16Gly genotype experienced a significant increase in morning PEFR (+14",
"    <span class=\"nowrap\">",
"     L/m).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment response to LABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two",
"    small retrospective cohort studies found that patients with the Arg16Arg genotype had worse response to the long-acting beta-agonist (LABA)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    compared with patients with the Gly16Gly genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]; however, most larger prospective studies have not confirmed these results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double blind study of 2250 patients with more severe asthma (833 Gly16Gly, 1028 Gly16Arg, 361 Arg16Arg) on regular inhaled glucocorticoids and either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      , no difference between genotypes was found in the frequency of exacerbations or measures of asthma control [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/49\">",
"       49",
"      </a>",
"      ]. As all of the patients were taking inhaled glucocorticoids and used limited doses of short acting beta agonists (SABA), this study does not resolve whether beta-adrenergic receptor polymorphism affects outcomes in patients on LABA monotherapy or frequent dosing of SABA.",
"     </li>",
"     <li>",
"      To evaluate whether beta-adrenergic receptor polymorphisms affect outcomes in patients on LABA monotherapy, 544 subjects, whose asthma was poorly controlled on SABA alone, were randomly assigned based on Arg16Gly genotype to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      alone or salmeterol with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/51\">",
"       51",
"      </a>",
"      ]. The primary efficacy measure was morning peak expiratory flow rate. No difference was found for modulation of the treatment response due to beta-adrenergic receptor genotype variation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, an observational study of 1182 young asthmatics suggested that exacerbations were more common in those individuals carrying the Arg16 allele who were exposed to daily beta-2 agonists, regardless of whether the exposure was to SABA or LABA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that any clinical effects driven by genetic variation are likely to be minimized by prescribing LABAs in combination with inhaled glucocorticoids. In accordance with current asthma treatment guidelines, we do not recommend LABA monotherapy or regular dosing of SABA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18974159\">",
"    <span class=\"h3\">",
"     Response to ultra-LABAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of very long acting once daily beta-2 agonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/59/26549?source=see_link\">",
"     indacaterol",
"    </a>",
"    and vilanterol has increased the number of beta-2 agonists available for use in patients with COPD. Whether clinical responses to ultra-LABAs are affected by beta-2 receptor polymorphism has not been determined, although in vitro responses show similar profiles to existing LABAs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Beta agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute treatment response to SABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Arg16Arg genotype has been associated with an increased physiological response to a single dose of short-acting beta-agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. This was best demonstrated by a study of 269 children with asthma who underwent genotyping, then had spirometry measured before and after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients with the Arg16Arg genotype were 5.3 times more likely to have an increase in FEV1 of more than 15 percent, compared to patients with the Gly16Gly genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Disease risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been a number of studies examining possible relationships between beta-2 receptor polymorphisms and disease risk with conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 60 families with multiple asthmatic family members, no association was found between asthma severity and either the glycine or glutamate polymorphisms at the 16th and 27th positions of the beta-2 adrenergic receptor",
"      <span class=\"nowrap\">",
"       (Gly16/Gln27),",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/43\">",
"       43",
"      </a>",
"      ]. Similarly, in a random sample of 332 individuals, neither the glycine nor the glutamate polymorphism was associated with the presence of clinician-diagnosed asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to the negative results of the studies described above, other studies have reported an association between disease and beta-2 receptor polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In one study of 167 patients with asthma and 84 control subjects, the",
"      <span class=\"nowrap\">",
"       Gly16/Gln27",
"      </span>",
"      genotype was more prevalent in patients with moderate asthma than in patients with mild asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/39\">",
"       39",
"      </a>",
"      ]. In another study, the Gly16 polymorphism correlated with nocturnal asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of the UK 1958 birth cohort examined relationships between beta-2 adrenergic receptor polymorphism and asthma risk [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/53\">",
"       53",
"      </a>",
"      ]. In this study, which included 8018 subjects, no overall association was seen between the codon 16, 27, or 164 polymorphisms and asthma risk either in children or adults, although the Arg16Gln27 haplotype was associated weakly with progression of wheezing illness from childhood into adult life. This study shows that at least in the UK population, these polymorphisms are not important determinants of asthma risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cross talk with other signaling cascades",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on transgenic mice either lacking or overexpressing the beta-2 adrenergic receptor have provided additional insight into the regulation of airway responses by the beta-2 adrenergic receptor pathway. Although mice with very high levels of beta-2 adrenergic receptor expression have dilated airways, mice with lower levels of overexpression actually have increased airway reactivity, while mice lacking the beta-2 adrenergic receptor demonstrate decreased airway responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15239/abstract/54\">",
"     54",
"    </a>",
"    ]. These counterintuitive findings are probably due to increased phospholipase C-beta1 expression in mice overexpressing the beta-2 adrenergic receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expression and coupling of beta-2 adrenergic receptors are dynamically controlled in airway cells by a variety of mechanisms that may modify the effect of receptor stimulation. Tachyphylaxis following chronic beta agonist stimulation is demonstrable in vitro, but the clinical impact of this phenomenon is less well defined.",
"   </p>",
"   <p>",
"    Common polymorphisms of the beta adrenergic receptor are found at amino acid positions 16 and 27. Studies examining the influence of these polymorphisms are conflicting; the weight of the evidence is that they do not increase the risk of developing asthma or the severity of asthma, but may be associated with a greater likelihood of asthma persisting from childhood to adulthood. Further study may clarify the precise role of these and other beta receptor polymorphisms in the genesis and course of asthma.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     Arg/Arg",
"    </span>",
"    polymorphism at position 16 of the beta-2 adrenergic receptor may be associated with adverse outcomes related to regular use of short acting beta agonists (SABA). However, at least within a clinical trial setting, this polymorphism does not appear to affect the safety or efficacy of currently available long-acting beta agonists (LABAs), when used in combination with inhaled glucocorticoids.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/1\">",
"      Kobilka BK, Dixon RA, Frielle T, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 1987; 84:46.",
"     </a>",
"    </li>",
"    <li>",
"     Hall IP, Tattersfield AE. &szlig;-agonists. In: Asthma, 3rd ed, Clark TJ, Godfrey S, Lee T (Eds), Chapman and Hall, London 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/3\">",
"      Kume H, Hall IP, Washabau RJ, et al. Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J Clin Invest 1994; 93:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/4\">",
"      Shore SA, Laporte J, Hall IP, et al. Effect of IL-1 beta on responses of cultured human airway smooth muscle cells to bronchodilator agonists. Am J Respir Cell Mol Biol 1997; 16:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/5\">",
"      Koto H, Mak JC, Haddad EB, et al. Mechanisms of impaired beta-adrenoceptor-induced airway relaxation by interleukin-1beta in vivo in the rat. J Clin Invest 1996; 98:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/6\">",
"      Collins S, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. J Biol Chem 1988; 263:9067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/7\">",
"      Taylor DR, Hancox RJ. Interactions between corticosteroids and beta agonists. Thorax 2000; 55:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/8\">",
"      Bai TR. Abnormalities in airway smooth muscle in fatal asthma. A comparison between trachea and bronchus. Am Rev Respir Dis 1991; 143:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/9\">",
"      Whicker SD, Armour CL, Black JL. Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists. Pulm Pharmacol 1988; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/10\">",
"      Goldie RG, Spina D, Henry PJ, et al. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol 1986; 22:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/11\">",
"      Tattersfield AE. Tolerance to beta-agonists. Bull Eur Physiopathol Respir 1985; 21:1s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/12\">",
"      Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/13\">",
"      Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/14\">",
"      Juniper EF, Johnston PR, Borkhoff CM, et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995; 151:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/15\">",
"      Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/16\">",
"      D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/17\">",
"      Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/18\">",
"      Apter AJ, Reisine ST, Willard A, et al. The effect of inhaled albuterol in moderate to severe asthma. J Allergy Clin Immunol 1996; 98:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/19\">",
"      Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am J Respir Crit Care Med 1996; 154:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/20\">",
"      van Schayck CP, Dompeling E, van Herwaarden CL, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/21\">",
"      Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/22\">",
"      Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/23\">",
"      Litonjua AA, Silverman EK, Tantisira KG, et al. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest 2004; 126:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/24\">",
"      Green SA, Turki J, Bejarano P, et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/25\">",
"      Dewar JC, Wheatley AP, Venn A, et al. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 1998; 28:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/26\">",
"      Ramsay CE, Hayden CM, Tiller KJ, et al. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 1999; 29:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/27\">",
"      Green SA, Cole G, Jacinto M, et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268:23116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/28\">",
"      Thomsen M, Nordestgaard BG, Sethi AA, et al. &beta;2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012; 39:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/29\">",
"      Scott MG, Swan C, Wheatley AP, Hall IP. Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol 1999; 126:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/30\">",
"      McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/31\">",
"      Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/32\">",
"      Lipworth B, Koppelman GH, Wheatley AP, et al. Beta2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/33\">",
"      Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005; 171:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/34\">",
"      Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/35\">",
"      Tan S, Hall IP, Dewar J, et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/36\">",
"      Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/37\">",
"      Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/38\">",
"      Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/39\">",
"      Weir TD, Mallek N, Sandford AJ, et al. beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/40\">",
"      Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/41\">",
"      Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/42\">",
"      Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/43\">",
"      Dewar JC, Wilkinson J, Wheatley A, et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/44\">",
"      Carroll CL, Stoltz P, Schramm CM, Zucker AR. Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009; 135:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/45\">",
"      Basu K, Palmer CN, Tavendale R, et al. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 2009; 124:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/46\">",
"      Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/47\">",
"      Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/48\">",
"      Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/49\">",
"      Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/50\">",
"      Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/51\">",
"      Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/52\">",
"      Sayers I, Hawley J, Stewart CE, et al. Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist. Br J Pharmacol 2009; 158:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/53\">",
"      Hall IP, Blakey JD, Al Balushi KA, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006; 368:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15239/abstract/54\">",
"      McGraw DW, Almoosa KF, Paul RJ, et al. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 2003; 112:619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 539 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15239=[""].join("\n");
var outline_f14_56_15239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL RECEPTOR REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RECEPTOR DYSFUNCTION IN ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECEPTOR POLYMORPHISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment response to regular SABA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment response to LABA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18974159\">",
"      - Response to ultra-LABAs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute treatment response to SABA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Disease risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cross talk with other signaling cascades",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15240="Chest pain of esophageal origin";
var content_f14_56_15240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chest pain of esophageal origin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Donald O Castell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15240/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/56/15240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurring substernal chest pain, not due to coronary artery disease, is a common clinical problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .) More than 50 percent of patients presenting to emergency facilities with unexplained chest pain will have coronary disease ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Unfortunately, these patients are usually sent home without a diagnosis and remain confused and concerned about the origin of their pain. Most of them are evaluated initially by a cardiologist or by emergency department physicians who often fail to pursue evaluation for other possible causes for the chest pain, since the overall risk of life-threatening events is so much higher with coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is ample documentation that this large group of patients with unexplained chest pain represents a major economic burden because of continued utilization of physician and emergency facilities for recurring pain attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/5\">",
"     5",
"    </a>",
"    ]. Even knowing that they have a negative coronary arteriogram fails to relieve concern or lead to sustained improvement in these patients. One report, for example, surveyed functional status in patients with chest pain and negative coronary arteriograms more than one year after the initial evaluation: 51 percent were unable to work, 47 percent noted limited activity because of their pain, and 44 percent still believed they had coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF ESOPHAGEAL CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential esophageal origin for recurring \"noncardiac\" chest pain has been considered likely since William Osler first suggested in 1892 that esophageal spasm might cause these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, over the ensuing years, an empiric diagnosis of \"esophageal spasm\" has been applied to patients with unexplained chest pain.",
"   </p>",
"   <p>",
"    However, more recent studies indicate that true spasm is not a likely cause for recurring unexplained chest pain. A study of 910 patients with negative coronary angiograms undergoing esophageal motility testing found that 28 percent of patients had abnormal motility while only 10 percent of those (ie, 2.8 percent of the total patients) had evidence of esophageal spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/8\">",
"     8",
"    </a>",
"    ]. Other studies have confirmed that spasm is identified in fewer than 10 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In a series that included 140 patients with noncardiac chest pain, the most common esophageal motor abnormality was a hypotensive lower esophageal sphincter (61 percent of patients) while nutcracker esophagus and nonspecific motility disorders were present in only 10 percent of patients each [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link\">",
"     \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal chest pain may result from abnormal processes inside the esophagus, abnormal perception of otherwise normal stimuli due to decreased pain threshold (ie, esophageal hypersensitivity) or abnormal transmission of stimuli in the peripheral and central nervous system. Painful esophageal sensations are considered to result from the stimulation of chemoreceptors by acid or hyperosmolar substances, mechanoreceptors by distension or abnormal contractions and thermoreceptors by hot or cold food [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of gastric acid in the genesis of chest pain is supported by both provocation of chest pain with acid infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/13\">",
"     13",
"    </a>",
"    ] and improvement of esophageal chest pain with acid suppression therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/14\">",
"     14",
"    </a>",
"    ]. The role of esophageal distension or contraction is supported by balloon distention studies indicating that increased wall tension can induce esophageal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/15\">",
"     15",
"    </a>",
"    ] as well as evidence of prolonged esophageal wall contractions detected by endoscopic ultrasound during episodes of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroesophageal reflux is the most common cause of non-cardiac chest pain. The development of ambulatory intraesophageal pH monitoring has demonstrated that approximately 50 percent of patients with recurrent noncardiac chest pain have abnormal esophageal acid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ]. This was illustrated in a study in which testing for esophageal disease with a variety of approaches was performed in patients with chest pain and normal coronary angiograms; abnormal ambulatory esophageal pH monitoring was the most common abnormality (",
"    <a class=\"graphic graphic_table graphicRef82470 \" href=\"UTD.htm?14/14/14571\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/10\">",
"     10",
"    </a>",
"    ]. These observations have reinforced the importance of identifying the presence or absence of abnormal gastroesophageal reflux (GER) in the evaluation of these patients. Whether this requires prolonged pH monitoring or can be accomplished by an appropriate therapeutic trial remains controversial and will be discussed below.",
"   </p>",
"   <p>",
"    By comparison, endoscopy is a low yield procedure in this setting, with reports indicating that as few as 6 percent of patients have esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/10\">",
"     10",
"    </a>",
"    ]. The utility of esophageal motility testing has also declined compared to testing for GER in view of the awareness that esophageal spasm or other motility disorders have a low likelihood of being etiologic factors in chest pain syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Esophageal hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are considerable experimental data to indicate that some patients with noncardiac chest pain have a lower threshold for esophageal pain than normal subjects. Studies using intraesophageal balloon distension have shown that many patients with unexplained chest pain experience their pain at a lower volume of balloon inflation than that found in appropriate control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. An illustrative report evaluated 24 patients with chest pain in whom no disease could be identified on cardiac work-up, upper gastrointestinal endoscopy, esophageal motility studies, or 24-hour esophageal pH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/16\">",
"     16",
"    </a>",
"    ]. The first sensation was seen at a smaller volume in the patients versus controls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, typical chest pain could be reproduced in 20 of the patients (83 percent), while none of the controls complained of chest pain. Similar phenomena have been described with gastric distension in patients with functional dyspepsia and intestinal distension in patients with the irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology of irritable bowel syndrome\", section on 'Visceral hypersensitivity'",
"    </a>",
"    .) Studies using intraluminal ultrasonography suggest that muscle contractions producing thickening of the esophageal wall are associated with unexplained chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies combining esophageal balloon distension with recording of cerebral evoked potentials suggest that esophageal hyperalgesia represents altered cerebral processing of the sensory information rather than abnormal receptors within the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Possible mediators include serotonin, bradykinin, tachykinins, and neurotrophins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/24\">",
"     24",
"    </a>",
"    ]. Interestingly, some patients with cardiac syndrome X (microvascular angina with normal coronary arteries on arteriography) may have a similar problem in which there is altered sensory awareness to cardiac events, the so-called \"sensitive heart\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Provocative testing of the esophagus in patients with unexplained chest pain, including acid perfusion (Bernstein test),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    chloride stimulation (Tensilon test), or intraesophageal balloon distension are not used commonly in clinical practice. While a positive response to testing of this kind is generally believed to reinforce an esophageal etiology for the patient's pain, it does not clarify the specific mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/4,27,28\">",
"     4,27,28",
"    </a>",
"    ]. Thus, the esophageal etiology might represent GER, esophageal hyperalgesia, or even a hypercontracting or discoordinated esophageal motility abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach must include the exclusion of coronary disease using appropriate triage of all patients with an acute chest pain event [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/29\">",
"     29",
"    </a>",
"    ]. Depending upon the patient's risk factors, this may require only minimal testing or more definitive coronary angiography. It is well-established that a normal finding with the latter essentially eliminates life-threatening coronary disease as the cause of the chest pain. The CASS registry identified over 3100 patients with anginal-type chest pain, normal coronary arteries, and normal left ventricular function; these patients, some of whom might have had microvascular angina, had a 96 percent seven-year survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation often does not provide adequate clues to distinguish cardiac and esophageal pain. There are, however, several clues that suggest an esophageal etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain persisting for more than one hour",
"     </li>",
"     <li>",
"      Pain that typically occurs postprandially",
"     </li>",
"     <li>",
"      Lack of radiation of the pain",
"     </li>",
"     <li>",
"      Associated esophageal symptoms (heartburn, regurgitation, dysphagia)",
"     </li>",
"     <li>",
"      Pain relieved by antacid ingestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the exclusion of coronary disease, the patient's symptoms should not be ignored. In addition to reassuring the patient that the pain is not cardiac or life-threatening, identification of the likely source of the pain can significantly decrease the high cost of recurring physician and emergency department visits for unexplained pain events [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/31\">",
"     31",
"    </a>",
"    ]. Because of the high prevalence of GER in patients with recurring pain of sufficient frequency or severity to result in repeated physician or emergency department visits [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/10\">",
"     10",
"    </a>",
"    ], this entity should be excluded early in their evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef66387 \" href=\"UTD.htm?9/39/9840\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in patients presenting with pain does not necessarily indicate that the pain was cardiac in origin. A study of 459 patients with chest pain admitted from the emergency department found that, overall, nitroglycerin relieved the pain in 39 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/32\">",
"     32",
"    </a>",
"    ]. However, pain relief was achieved in a similar proportion of patients with and without coronary artery disease (35 percent",
"    <span class=\"nowrap\">",
"     (49/141)",
"    </span>",
"    versus 41 percent",
"    <span class=\"nowrap\">",
"     (113/275),",
"    </span>",
"    respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of an empiric trial of antireflux therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A response to an empiric trial with proton pump inhibitors is often used to implicate reflux as the cause of noncardiac chest pain. Two meta-analyses have estimated the accuracy of this approach compared with esophageal pH testing or endoscopy as the reference standard, both concluding that a clinical response to an empiric trial of a PPI performs fairly well as a diagnostic test for identifying pathologic reflux in patients with noncardiac chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of eight trials concluded that PPIs were approximately 50 percent more effective than placebo in improving chest pain (pooled risk ratio 0.54, 95% CI 0.41-0.71). Pooled sensitivity, specificity, and the diagnostic odds ratio (ie, the odds of a positive test in patients with abnormal acid reflux compared with the odds of a positive test in patients without abnormal acid reflux) were 80 and 74 percent, and 14 (95% CI 5.48-34.91) respectively. Most of the studies included in the meta-analysis defined a clinical response as a &gt;50 percent improvement in pain.",
"     </li>",
"     <li>",
"      A second meta-analysis of six studies found overall sensitivity and specificity of 80 (95% CI 71-87%) and 74 percent (95% CI 64-83%), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/34\">",
"       34",
"      </a>",
"      ]. The summary diagnostic odds ratio was 19.35 (95% CI 8.54-43.84).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential problem with these conclusions is the way in which endpoints were defined in the individual trials. A 50 percent decrease in pain is much less specific than complete pain relief; thus, the estimates of specificity may be optimistic. Furthermore, patients included in the primary studies were generally referred to tertiary care centers and had undergone a thorough evaluation for other causes of pain. Whether similar accuracy would be observed in a less selected group of patients with presumed noncardiac chest pain is unclear. An earlier meta-analysis found that a response to a PPI was not an accurate predictor of GERD when GERD was defined by endoscopy or pH studies, but primary studies of patients with noncardiac chest pain were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of empiric treatment was supported in a decision analysis in which strategies using initial empiric",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    were associated with an 11 percent improvement in diagnostic accuracy and a 43 percent reduction in the use of invasive diagnostic tests compared to traditional diagnostic approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/36\">",
"     36",
"    </a>",
"    ]. It was estimated that empiric treatment could yield a cost savings of $454 per patient compared to a strategy of beginning with endoscopy and proceeding with pH monitoring and manometry. However, this argument is weakened by the knowledge that endoscopy is not an important component of the initial diagnostic approach to these patients because of its low yield. A more recent study suggested that PPIs reduce chest pain events, emergency room visits, and hospitalizations for chest pain in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether one philosophically believes in the \"test first\" or \"treat first\" approach, the evolving standard of practice is to give an initial trial of high dose acid suppression. Optimal management of patients who do not respond is unclear. New technology that combines esophageal impedance testing with ambulatory pH monitoring will likely have a role in the management of such patients. This technique relies on changes in intraluminal electrical impedance to identify liquid reflux into the esophagus independent of pH. Thus, non-acid reflux episodes occurring in the acid-suppressed patient can be identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using an empiric trial, we recommend high-dose treatment for acid reflux, preferably with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    (40 mg twice daily)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (20 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    (20 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (30 mg twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    (40 mg twice daily) given prior to meals for a period of up to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/38\">",
"     38",
"    </a>",
"    ]. A positive symptom response strongly suggests that the chest pain is due to GER; treatment can then be adjusted to a level necessary to maintain control of recurring pain attacks.",
"   </p>",
"   <p>",
"    Some patients will have an initial \"false positive\" response representing a placebo effect. These patients are likely to have recurrent symptoms despite continued antireflux therapy. At that point, ambulatory esophageal combined impedance and pH monitoring on therapy can be advised to clarify an etiologic role for reflux. Such testing permits evaluation of the role of both acidic and non-acidic reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to respond to the trial of proton pump inhibition from the outset may not have reflux as a cause of their pain. Alternatively, up to 20 percent of such patients have continued acid secretion despite the doses of PPIs suggested above, suggesting that additional acid suppression may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Symptoms in other patients may be due to persistent non-acid reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/42\">",
"     42",
"    </a>",
"    ]. These possibilities can be distinguished with prolonged ambulatory combined impedance and pH monitoring while therapy is continued. The test should be performed with dual electrodes recording pH both in the distal esophagus and gastric fundus.",
"   </p>",
"   <p>",
"    As an alternative approach, esophageal and gastric pH monitoring alone (while maintaining the PPI therapy) will at least identify the 20 percent of these patients whose symptoms may be attributable to continued acid reflux. Other methods to detect non-acid reflux have individual limitations, including scintigraphy, intraesophageal bilirubin monitoring, and esophageal manometry. Extending esophageal pH monitoring from the traditional 24 hours to 48 hours (using a wireless pH monitoring system) improved detection of reflux in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Manometry, impedance testing and provocative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tests should be considered in most patients in whom GER has been clearly excluded as a cause of chest pain. However, appropriate therapy directed by the findings on these tests is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authorities prefer an initial trial of a calcium channel blocker in patients with chest pain that is presumed to be due to a motility disorder. As described below, our personal preference (after reflux has been excluded) is to perform combined esophageal manometry and impedance testing, including provocative testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    . Based upon this additional information, we make a decision as to whether esophageal dysmotility is a likely cause of the patients' symptoms and use this to guide additional therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting studies have been reported on the benefit of calcium channel blockers in the treatment of patients with diffuse esophageal spasm or hypercontracting motility (nutcracker esophagus or hypertensive lower esophageal sphincter). A positive response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    (240 to 360",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was found in one small prospective eight-week crossover, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Botox",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncontrolled study of 29 patients with chest pain with spastic esophageal motility disorders found that endoscopic injection of Botulinum toxin into the lower esophageal sphincter decreased symptoms in 72 percent of patients for a mean of seven months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , decrease esophageal contraction pressures through the increased tissue nitric oxide concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/47\">",
"     47",
"    </a>",
"    ]. There is preliminary evidence that they may be effective in patients with regularly-recurring chest pain associated with abnormal esophageal contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Sildenafil has also been associated with transient esophageal symptoms (mainly dysphagia and odynophagia) in patients without known esophageal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small, placebo-controlled, crossover trial of patients with presumed esophageal chest pain found that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    improved symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/51\">",
"     51",
"    </a>",
"    ]. In a preliminary phase of the trial the authors used esophageal impedance planimetry testing to evaluate the effects of intravenous (IV) theophylline on esophageal function. Compared with placebo, IV theophylline decreased chest pain thresholds, increased esophageal cross-sectional area and improved esophageal wall distensibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of tricyclic antidepressant medications may be effective for patients with abnormal sensory processing of esophageal events (the \"esophageal hyperalgesia\" syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/52\">",
"     52",
"    </a>",
"    ]. Such patients can be recognized because of a low threshold for perceiving discomfort with intraesophageal balloon distention, or symptoms noted during episodes of physiologic reflux during 24-hour pH monitoring.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    have shown encouraging results in prospective controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Of these, imipramine and related tricyclic antidepressant medications have shown the most encouraging results in long-term evaluations (see below). Limited experience suggests that the serotonin reuptake inhibitors (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ) may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/55\">",
"     55",
"    </a>",
"    ]. It has been proposed that the effect of low-dose tricyclic antidepressants is primarily due to a visceral analgesic action. Support for an effect of this kind with imipramine, 75 mg daily was demonstrated in a study in normal volunteers in which the pain threshold to esophageal balloon distention was raised compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients who respond to antidepressants appear to have a durable benefit. In a retrospective series, for example, initial treatment produced a benefit in 17 of 21 patients (81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15240/abstract/57\">",
"     57",
"    </a>",
"    ]. Of these, seven (41 percent) were treated successfully for an average of 2.6 years while five (29 percent) discontinued treatment with sustained benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       \"Patient information: Chest pain (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       \"Patient information: Chest pain (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal chest pain may result from abnormal processes inside the esophagus, abnormal perception of otherwise normal stimuli due to decreased pain threshold (ie, esophageal hypersensitivity) or abnormal transmission of stimuli in the peripheral and central nervous system. Gastroesophageal reflux is the most common cause of non-cardiac chest pain. The development of ambulatory intraesophageal pH monitoring has demonstrated that approximately 50 percent of patients with recurrent noncardiac chest pain have abnormal esophageal acid exposure. In contrast, true spasm is not a likely cause for recurring unexplained chest pain. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial approach must include the exclusion of coronary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"       \"Diagnostic approach to chest pain in adults\"",
"      </a>",
"      .) The clinical presentation often does not provide adequate clues to distinguish cardiac and esophageal pain. Features of pain that suggest an esophageal etiology include persistence of pain for more than one hour, postprandial occurrence of pain, lack of radiation, the presence of associated esophageal symptoms (heartburn, regurgitation, dysphagia), and relief by antacid ingestion.",
"     </li>",
"     <li>",
"      The accuracy of empiric antireflux treatment for the diagnosis and treatment of noncardiac chest pain is uncertain. However, it is conceivable that such an approach may be more cost-effective than routine use of ambulatory pH monitoring. Thus, we recommend an empiric trial with a proton pump inhibitor for eight weeks (",
"      <a class=\"graphic graphic_algorithm graphicRef66387 \" href=\"UTD.htm?9/39/9840\">",
"       algorithm 1",
"      </a>",
"      ). Reasonable options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      (40 mg twice daily)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      (20 mg twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"       rabeprazole",
"      </a>",
"      (20 mg twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      (30 mg twice daily), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      (40 mg twice daily) given 30 minutes prior to meals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Role of an empiric trial of antireflux therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a poor response should be referred for ambulatory combined impedance-pH monitoring (on therapy). An alternative, when this technique is unavailable, is standard esophageal and gastric pH monitoring while on therapy. Those with abnormal acid or nonacid reflux should be treated for GERD. Manometry and provocative tests can be considered for other patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Manometry, impedance testing and provocative testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with diffuse esophageal spasm, nutcracker esophagus, or a hypertensive lower esophageal sphincter, we suggest a calcium channel blocker or nitrate initially, with Botox injection or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      a consideration in resistant cases. Although initial anecdotal reports are encouraging, neither approach has been supported by prospective controlled trials. In those with a positive provocative test, we recommend a trial of a visceral analgesic (primarily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      starting at 25 to 50 mg at bedtime and increasing up to 150 mg daily). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Calcium channel blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Botox'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our initial experience with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      in patients with severe chest pain and esophageal dysmotility (unresponsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      up to 360 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      10 mg four times daily) has suggested that a single daily dose (50 mg) is associated with relief of pain and an associated decrease in the amplitude of esophageal contractions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Phosphodiesterase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/1\">",
"      Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/2\">",
"      Katz PO, Castell DO. Approach to the patient with unexplained chest pain. Am J Gastroenterol 2000; 95:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/3\">",
"      Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA 2002; 288:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/4\">",
"      Ghillebert G, Janssens J. Provocation tests versus 24-h pH and pressure measurements. Eur J Gastroenterol Hepatol 1995; 7:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/5\">",
"      Richter JE, Bradley LA, Castell DO. Esophageal chest pain: current controversies in pathogenesis, diagnosis, and therapy. Ann Intern Med 1989; 110:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/6\">",
"      Ockene IS, Shay MJ, Alpert JS, et al. Unexplained chest pain in patients with normal coronary arteriograms: a follow-up study of functional status. N Engl J Med 1980; 303:1249.",
"     </a>",
"    </li>",
"    <li>",
"     Osler W. Principles and Practice of Medicine, D Appleton and Co, New York 1892. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/8\">",
"      Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 1987; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/9\">",
"      Dalton CB, Castell DO, Hewson EG, et al. Diffuse esophageal spasm. A rare motility disorder not characterized by high-amplitude contractions. Dig Dis Sci 1991; 36:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/10\">",
"      Cherian P, Smith LF, Bardhan KD, et al. Esophageal tests in the evaluation of non-cardiac chest pain. Dis Esophagus 1995; 8:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/11\">",
"      Dekel R, Pearson T, Wendel C, et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain - the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther 2003; 18:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/12\">",
"      Sengupta JN. An overview of esophageal sensory receptors. Am J Med 2000; 108 Suppl 4a:87S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/13\">",
"      Richter JE, Hewson EG, Sinclair JW, Dalton CB. Acid perfusion test and 24-hour esophageal pH monitoring with symptom index. Comparison of tests for esophageal acid sensitivity. Dig Dis Sci 1991; 36:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/14\">",
"      Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/15\">",
"      Paterson WG, Wang H, Vanner SJ. Increasing pain sensation to repeated esophageal balloon distension in patients with chest pain of undetermined etiology. Dig Dis Sci 1995; 40:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/16\">",
"      Balaban DH, Yamamoto Y, Liu J, et al. Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology 1999; 116:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/17\">",
"      Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/18\">",
"      DeMeester TR, O'Sullivan GC, Bermudez G, et al. Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg 1982; 196:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/19\">",
"      Richter JE, Barish CF, Castell DO. Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986; 91:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/20\">",
"      Hobson AR, Furlong PL, Sarkar S, et al. Neurophysiologic assessment of esophageal sensory processing in noncardiac chest pain. Gastroenterology 2006; 130:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/21\">",
"      Rao SS, Gregersen H, Hayek B, et al. Unexplained chest pain: the hypersensitive, hyperreactive, and poorly compliant esophagus. Ann Intern Med 1996; 124:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/22\">",
"      Smout AJ, DeVore MS, Dalton CB, Castell DO. Cerebral potentials evoked by oesophageal distension in patients with non-cardiac chest pain. Gut 1992; 33:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/23\">",
"      Sarkar S, Aziz Q, Woolf CJ, et al. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/24\">",
"      Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/25\">",
"      Cannon RO 3rd. The sensitive heart. A syndrome of abnormal cardiac pain perception. JAMA 1995; 273:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/26\">",
"      B&ouml;rjesson M, Albertsson P, Dellborg M, et al. Esophageal dysfunction in syndrome X. Am J Cardiol 1998; 82:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/27\">",
"      Hewson EG, Dalton CB, Richter JE. Comparison of esophageal manometry, provocative testing, and ambulatory monitoring in patients with unexplained chest pain. Dig Dis Sci 1990; 35:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/28\">",
"      Barish CF, Castell DO, Richter JE. Graded esophageal balloon distention. A new provocative test for noncardiac chest pain. Dig Dis Sci 1986; 31:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/29\">",
"      Goldman L, Kirtane AJ. Triage of patients with acute chest pain and possible cardiac ischemia: the elusive search for diagnostic perfection. Ann Intern Med 2003; 139:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/30\">",
"      Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/31\">",
"      Ward BW, Wu WC, Richter JE, et al. Long-term follow-up of symptomatic status of patients with noncardiac chest pain: is diagnosis of esophageal etiology helpful? Am J Gastroenterol 1987; 82:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/32\">",
"      Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med 2003; 139:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/33\">",
"      Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/34\">",
"      Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med 2005; 165:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/35\">",
"      Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/36\">",
"      Ofman JJ, Gralnek IM, Udani J, et al. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/37\">",
"      Liuzzo JP, Ambrose JA, Diggs P. Proton pump inhibitors for patients with coronary artery disease associated with reduced chest pain, emergency department visits, and hospitalizations. Clin Cardiol 2005; 28:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/38\">",
"      Castell DO, Katz PO. The acid suppression test for unexplained chest pain. Gastroenterology 1998; 115:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/39\">",
"      Tutuian R, Vela MF, Shay SS, Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol 2003; 37:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/40\">",
"      Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/41\">",
"      Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/42\">",
"      Shay SS, Sifrim D, Tutuian R, et al. Multichannel intraluminal impedance in evaluation of patients with persistent GERD symptoms despite proton pump inhibitors (abstract). Gastroenterology 2003; 124 (Suppl 1):A537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/43\">",
"      Prakash C, Clouse RE. Wireless pH monitoring in patients with non-cardiac chest pain. Am J Gastroenterol 2006; 101:446.",
"     </a>",
"    </li>",
"    <li>",
"     Tack J, Janssens J. The esophagus and noncardiac chest pain. In: The Esophagus, 4th ed, Castell D, Richter J (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.634.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/45\">",
"      Cattau EL Jr, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/46\">",
"      Miller LS, Pullela SV, Parkman HP, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 2002; 97:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/47\">",
"      Rhee PL, Hyun JG, Lee JH, et al. The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults. Am J Gastroenterol 2001; 96:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/48\">",
"      Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/49\">",
"      Agrawal A, Tutuian R, Hila A, Castell DO. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci 2005; 50:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/50\">",
"      Kim BJ, Rhee PL, Son HJ. Sildenafil prescribed for erectile dysfunction may induce esophageal symptoms. J Clin Gastroenterol 2005; 39:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/51\">",
"      Rao SS, Mudipalli RS, Remes-Troche JM, et al. Theophylline improves esophageal chest pain--a randomized, placebo-controlled study. Am J Gastroenterol 2007; 102:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/52\">",
"      Nguyen TM, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther 2012; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/53\">",
"      Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/54\">",
"      Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/55\">",
"      Varia I, Logue E, O'connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000; 140:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/56\">",
"      Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15240/abstract/57\">",
"      Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999; 44:2373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2262 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15240=[""].join("\n");
var outline_f14_56_15240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY OF ESOPHAGEAL CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Esophageal hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of an empiric trial of antireflux therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Manometry, impedance testing and provocative testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Botox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2262|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/39/9840\" title=\"algorithm 1\">",
"      Dx esophageal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/14/14571\" title=\"table 1\">",
"      Eso tests noncardiac chest pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=related_link\">",
"      Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15241="Diagnosis, treatment, and prevention of lymphatic filariasis";
var content_f14_56_15241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis, treatment, and prevention of lymphatic filariasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15241/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/56/15241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filariasis is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. Three species cause lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Infection is transmitted by mosquito vectors; humans are definitive hosts. Lymphatic filariasis is a major cause of disfigurement and disability in endemic areas, leading to significant economic and psychosocial impact.",
"   </p>",
"   <p>",
"    The diagnosis, treatment, and prevention of lymphatic filariasis will be reviewed here. The epidemiology, pathogenesis, and clinical features of lymphatic filariasis and other filarial infections, including onchocerciasis, loiasis, and mansonellosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lymphatic filariasis is based upon clinical and epidemiologic clues together with laboratory evaluation. Diagnostic tests for W. bancrofti include antigen testing and examination of blood to detect microfilariae. Antigen testing is a valuable diagnostic tool (but has limitations as described below). Examination of blood smears is an acceptable alternative in settings where antigen testing is not available; the sensitivity is increased with the number of smears evaluated. Diagnosis of Brugian filariasis requires blood smear examination. Ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphoscintigraphy can also be useful diagnostic tools. &nbsp;",
"   </p>",
"   <p>",
"    Peripheral blood eosinophilia is common and may exceed",
"    <span class=\"nowrap\">",
"     3000/microL.",
"    </span>",
"    The frequency of eosinophilia due to filariasis is difficult to determine since other helminth infections frequently coexist among individuals in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/1\">",
"     1",
"    </a>",
"    ]. Other nonspecific laboratory findings include microscopic hematuria and proteinuria; these may be present in individuals with renal system involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\", section on 'Renal involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Blood smears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of blood smears for microfilariae should be performed in all individuals in whom the diagnosis of filariasis is suspected. Both Bancroftian and Brugian filariasis tend to demonstrate nocturnal periodicity; the greatest number of microfilariae can be found in blood between 10 pm and 2 am, which is the peak biting time of the mosquito vectors. Thus, ideally blood should be drawn during this window. Exceptions include subperiodic variants. In the South Pacific, W. bancrofti microfilariae may be present even during day time hours; there are also some subperiodic variants of Brugian filariasis.",
"   </p>",
"   <p>",
"    Microfilariae stain with Wright's or Giemsa stains. Among patients in endemic areas &gt;10,000 microfilariae per mL of infected blood may be observed. Blood smears generally contain approximately 20 microL of blood; microfilariae may be observed on blood smears, although detection may be difficult. A technique to concentrate 1 mL blood volumes for examination may be required to make the diagnosis. This is generally performed with centrifugation (Knott's technique) or with the aid of a Nucleopore filter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three species can be differentiated from each other and from other filarial nematodes by their morphologic characteristics (",
"    <a class=\"graphic graphic_picture graphicRef69151 \" href=\"UTD.htm?14/55/15218\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54644 \" href=\"UTD.htm?24/52/25410\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66440 \" href=\"UTD.htm?29/27/30132\">",
"     picture 3",
"    </a>",
"    ). W. bancrofti and both Brugia species have an acellular sheath which stains and is visible on light microscopy. B. malayi has terminal and subterminal nuclei in its tail; W. bancrofti has no nuclei in its tail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests have been developed to detect either antifilarial antibodies or circulating filarial antigens.",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) techniques have been used as research tools to detect filarial infection in humans and to assess prevalence of microfilarial infection among mosquitoes although they are not commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antigen tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various methods of serum antigen detection have been developed using monoclonal antibodies. The assays detect the presence of filarial adult worms, so may be positive even in amicrofilaremic individuals. These tests have variable sensitivity and specificity, but overall have greater sensitivity than blood smears for detection of microfilariae [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, antigen levels remain stable during the day and night, so these tests can be performed at any time. Filarial antigen tests are available for diagnosis of W. bancrofti infections but are not yet available for Brugian filariasis.",
"   </p>",
"   <p>",
"    Two types of circulating filarial antigen (CFA) tests are available: an Og4C3 monoclonal antibody-based ELISA assay for W. bancrofti which gives a quantitative result which correlates with adult worm burden [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/6\">",
"     6",
"    </a>",
"    ], and an immunochromatographic technique (ICT) card-based assay which gives only qualitative results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Og4C3 ELISA assay has excellent specificity and better sensitivity than microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one study including 282 microfilaremic individuals in Brazil, the sensitivity of the Og4C3 at microfilarial densities of &lt; 1, 1-30, and &gt; 30 microfilariae per mL of blood was 72, 98, and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/10\">",
"     10",
"    </a>",
"    ]. In another study including 674 individuals from rural areas of Papua New Guinea, the Og4C3 CFA test detected twice as many cases as blood smear evaluation and also detected many asymptomatic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the test cannot exclude filarial infection as a cause of pathology since both microfilariae and filarial antigens may be undetectable in treated or burnt out infection, even in the setting of lymphatic damage. The tests may be useful for following patients after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Qualitative ICT tests are very useful in field surveys, and sensitivity of ICT is higher than that of the Og4C3 ELISA test [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the ICT may remain positive in microfilaria-negative individuals for up to three years after treatment, suggesting it is not as good for follow-up surveys after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ELISA that uses urine samples and detects filaria-specific IgG4 has also been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/17\">",
"     17",
"    </a>",
"    ]. This ELISA has a reported sensitivity and specificity of 95 and 99 percent, respectively, but it is not commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6727038\">",
"    <span class=\"h3\">",
"     Antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests for filarial antibodies that detect elevated levels of IgG and IgE are available. However, these assays do not differentiate between the various types of filarial infections, can cross react with other helminths, and cannot distinguish between active and past infections. Therefore they are not useful in endemic areas, but may be useful among travelers or expatriates.",
"   </p>",
"   <p>",
"    Newer assays are being developed that use secretory antigens or specific reagents to detect antibody isotypes or subclasses. Specific antifilarial IgG4 antibodies are thought to be a marker of active infection (in contrast to total IgG) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/19\">",
"     19",
"    </a>",
"    ]. Assays that use filarial-specific IgG4 levels have been shown to have &gt;96 percent sensitivity in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, filarial-specific IgE levels have been used in some studies instead of total IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These assays are not widely available but may be obtained from the Laboratory of Parasitic Diseases at the National Institutes of Health (NIH) at 301-496-5398.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound and lymphoscintigraphic techniques can be used to detect the presence of adult worms in lymphatic vessels. Living worms tend to be in continuous motion, which can be detected on ultrasound; this has been described as the \"filarial dance\" sign. Lymphatics containing worms can be distinguished from blood vessels by irregular movement on Doppler evaluation. Ultrasound can localize worms within lymphatics (particularly in the epididymal lymphatics) and can assess viability (",
"    <a class=\"graphic graphic_movie graphicRef56312 \" href=\"UTD.htm?34/23/35199\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/22\">",
"     22",
"    </a>",
"    ]. In some cases, worms can be visualized in the breast lymphatics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/23\">",
"     23",
"    </a>",
"    ]. Detection of motion on ultrasound has also been used to monitor the effectiveness of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, contrast lymphangiography was used to visualize lymphatic vessels. However, this procedure can damage vessels, so has largely been replaced by lymphoscintigraphy. Lymphoscintigraphy is a useful tool for assessing the extent of lymphatic damage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/26\">",
"     26",
"    </a>",
"    ]. Adult worms may be directly visible within the lymphatics, and massive lymphatic dilation may be observed surrounding and beyond the adult worms. Lymphatic abnormalities may also be detectable even in asymptomatic stages of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6728213\">",
"    <span class=\"h2\">",
"     Evaluating for coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients from areas where onchocerciasis or loiasis are endemic (",
"    <a class=\"graphic graphic_figure graphicRef81417 \" href=\"UTD.htm?30/55/31606\">",
"     figure 1",
"    </a>",
"    ), evaluation for these infections should be pursued prior to treatment. Administration of diethylcarbamazine (DEC) for treatment of lymphatic filariasis in the setting of onchocerciasis coinfection can induce an inflammatory reaction. In addition, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    for treatment of lymphatic filariasis in the setting of loiasis coinfection can also induce an inflammatory reaction. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diethylcarbamazine'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of therapy for treatment of lymphatic filariasis requires an understanding of the microfilaricidal and macrofilaricidal activity of therapeutic agents. The epidemiology of other filarial diseases is also important; in regions where loiasis and onchocerciasis may coexist with lymphatic filariasis, additional consideration is important for minimizing the likelihood of adverse effects.",
"   </p>",
"   <p>",
"    Most of the studies regarding the efficacy of various regimens are derived from data from mass chemotherapy programs. These data are helpful in determining the relative efficacy of the drugs and combinations in terms of microfilaricidal and macrofilaricidal activity, but do not necessarily provide optimal data on management of infected individuals, particularly for patients outside of endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729788\">",
"    <span class=\"h3\">",
"     Microfilaricidal therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Diethylcarbamazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diethylcarbamazine (DEC), a piperazine derivative, is a potent microfilaricidal agent with activity against W. bancrofti, B. malayi, and B. timori [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/28\">",
"     28",
"    </a>",
"    ]. The mechanism of action is uncertain; it is thought to alter microfilarial surface membranes or inhibit filarial release of immunomodulatory eicosanoids, thereby enhancing destruction via host immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of DEC include fever, headache, anorexia, nausea, and arthralgias. These effects are likely attributable to the host response following death of microfilariae (systemic reactions) and damage to adult worms (local reactions). Dying microfilariae probably release lipopolysaccharide-like proteins from endosymbiotic Wolbachia organisms within the filariae [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These reactions are more severe with onchocerciasis and loiasis; thus, evaluation for these coinfections should be pursued in patients from endemic areas prior to administering DEC. Management consists of administration of antipyretic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiinflammatory agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DEC should be avoided in pregnancy. Animal studies have not demonstrated teratogenicity. It is not excreted in breast milk and is considered safe during lactation.",
"   </p>",
"   <p>",
"    DEC is not distributed for use in the United States but can be obtained from the Centers for Disease Control and Prevention (CDC) under an Investigational New Drug (IND) protocol (Centers for Disease Control and Prevention Drug Service, Atlanta, GA 30333; telephone 404-639-2888) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of DEC to salt in endemic areas has been shown to be an effective in reducing microfilarial prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3730852\">",
"     'Mass treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Ivermectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    has microfilaricidal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], but does not have significant macrofilaricidal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/9,12,24,38\">",
"     9,12,24,38",
"    </a>",
"    ]. Therefore the reduction in microfilaremia is not sustained without repeat dosing. The clinical benefit of ivermectin is uncertain given the lack of activity against adult worms, which play an important role in the pathogenesis of lymphangitis and lymphedema. Ivermectin may have some effect in reducing the fertility of worms (in addition to its microfilaricidal activity).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is at least as effective as DEC in reducing microfilaremia due to Bancroftian filariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]; a single dose has been shown to reduce microfilaremia by approximately 90 percent even one year after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. One study in South India demonstrated that a single dose of ivermectin (150",
"    <span class=\"nowrap\">",
"     microgram/kg)",
"    </span>",
"    was approximately equivalent to a 12-day course of DEC in suppressing microfilaremia for three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    may be administered to patients with onchocerciasis coinfection, but is contraindicated in patients with loiasis coinfection. Patients with loiasis and high microfilaremia levels can develop encephalopathy following treatment with ivermectin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link&amp;anchor=H17#H17\">",
"     \"Loiasis (Loa loa infection)\", section on 'Ivermectin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729976\">",
"    <span class=\"h4\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    has both microfilaricidal and macrofilaricidal activity against W. bancrofti [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Doxycycline'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729903\">",
"    <span class=\"h3\">",
"     Macrofilaricidal therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730041\">",
"    <span class=\"h4\">",
"     Diethylcarbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to microfilaricidal activity, diethylcarbamazepine (DEC) has macrofilaricidal activity, likely via hyperpolarization leading to immobilization of adult worms. Estimates suggest DEC kills approximately 50 percent of adult worms, and its effect on adult worms in turn decreases the microfilarial burden [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diethylcarbamazine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730034\">",
"    <span class=\"h4\">",
"     Albendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    has macrofilaricidal activity but does not have microfilaricidal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;A promising alternative approach to attacking the worm directly is to focus treatment against Wolbachia, an intracellular bacterial symbiont of filarial parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link&amp;anchor=H6728508#H6728508\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\", section on 'Wolbachia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    appears to improve macrofilaricidal activity and may decrease side effects attributable to release of Wolbachia antigens in patients with detectable microfilaremia. Doxycycline has been shown to be effective in the setting of both W. bancrofti and B. malayi infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial including 72 Tanzanian patients with Bancroftian filariasis, patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg daily for eight weeks) had elimination of microfilaremia and diminished detectability of adult worms compared with patients who received placebo (22 versus 88 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/42\">",
"       42",
"      </a>",
"      ]. Subsequent trials have demonstrated that shorter regimens (four or six weeks may also be sufficient) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27,48,49\">",
"       27,48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial including 161 Indonesian patients with Brugian filariasis, a six week course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      reduced the prevalence of microfilaremia compared to placebo (77 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also some evidence that a six week regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    may ameliorate some clinical problems associated with active filarial infection such as lymph vessel dilation and hydrocele [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/51\">",
"     51",
"    </a>",
"    ]. Progression of lymphedema may also be ameliorated or reversed in early stages [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to antimicrobial therapy for lymphatic filariasis is uncertain. Since much of the data regarding the efficacy of various regimens are derived from data from mass chemotherapy programs, these data are helpful in determining the relative efficacy of the drugs and combinations in terms of microfilaricidal and macrofilaricidal activity, but do not necessarily provide optimal data on management of infected individuals, particularly for patients outside of endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with chronic complications, drug therapy may not improve the overall prognosis because fibrosis may have already irreversibly destroyed lymphatics. However, it is prudent to attempt therapy with the aim of killing any remaining viable adult worms and diminishing parasite load.",
"   </p>",
"   <p>",
"    For asymptomatic individuals with microfilaremia, most favor treatment to prevent disease progression, although the degree of benefit is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730263\">",
"    <span class=\"h4\">",
"     Individuals in areas with ongoing transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;For individuals with microfilaremia in areas with ongoing transmission of lymphatic filariasis (but not onchocerciasis or loiasis) where mass drug administration is delivered, treatment with diethylcarbamazine (DEC) may be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"     27",
"    </a>",
"    ]. The Medical letter favors a two week course (Day 1: 50 mg orally, Day 2: 50 mg orally three times daily, Day 3: 100 mg orally three times daily, Days 4-14: 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    day orally in three divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/53\">",
"     53",
"    </a>",
"    ]. The Centers for Disease Control (CDC) favors a single 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/54\">",
"     54",
"    </a>",
"    ]. The short course is known to be effective for reducing levels of microfilariae [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/55\">",
"     55",
"    </a>",
"    ], although it is not known whether low doses or short courses are effective for eliminating adult worms. For individuals in areas with ongoing transmission and no mass drug administration, administration of DEC daily for two weeks is warranted. Addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    might be beneficial but thus far there are no studies evaluating its benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730493\">",
"    <span class=\"h5\">",
"     Coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas co-endemic for onchocerciasis, administration of DEC can cause severe adverse effects. In these circumstances, treatment may be administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg orally once daily for four to six weeks) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    orally single dose) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg orally single dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link&amp;anchor=H24#H24\">",
"     \"Onchocerciasis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In areas co-endemic for loiasis, administration of DEC or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    can cause severe adverse effects in patients with high loads (&gt;2500",
"    <span class=\"nowrap\">",
"     microfilaria/mL",
"    </span>",
"    blood) of L. loa microfilariae. Therefore, blood microfilarial levels for Loa need to be ascertained prior to treatment. In the absence of high-level Loa microfilaremia, DEC can be administered. Issues related to management of high-level Loa microfilaremia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link&amp;anchor=H14#H14\">",
"     \"Loiasis (Loa loa infection)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730443\">",
"    <span class=\"h4\">",
"     Individuals in areas with low or no transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of individuals with low or no transmission consists of DEC (6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for a two week course).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (200 mg orally once daily for four to six weeks) may be added, although evidence for use of doxycycline is limited. Doxycycline therapy seems to improve macrofilaricidal activity and may decrease side effects attributable to release of Wolbachia antigens in patients with detectable microfilaremia. Doxycycline in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    has been shown to reduce microfilaremia as well as adverse reactions to treatment in infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/50\">",
"     50",
"    </a>",
"    ]. Other small trials have demonstrated that treatment with doxycycline followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    or DEC is efficacious in reducing microfilaremia and adverse reactions to antifilarial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/50,56\">",
"     50,56",
"    </a>",
"    ]. Follow-up of patients with detectable microfilaremia should include demonstrating resolution of microfilaremia on blood smears. Filarial antigen assays may decline more slowly over years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3730852\">",
"    <span class=\"h4\">",
"     Mass treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mass drug administration reduces the bloodborne reservoir of microfilariae to a level below that required for sustained transmission by local mosquito vectors (",
"    <a class=\"graphic graphic_figure graphicRef74534 \" href=\"UTD.htm?30/48/31495\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52000 \" href=\"UTD.htm?20/24/20871\">",
"     figure 3",
"    </a>",
"    ). The period of microfilaremia has been estimated to be four to six years, corresponding to the reproductive lifespan of the adult parasite. W. bancrofti has been designated as a target for elimination since there are no animal hosts. Elimination of Brugian filariasis is not feasible since this infection has a large domestic and wild animal reservoir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Global Program for the Elimination of Lymphatic Filariasis was organized in 2000 with a strategy of annual mass administration of single-dose antifilarial drugs for interrupting transmission of lymphatic filariasis in endemic areas (",
"    <a class=\"graphic graphic_figure graphicRef81417 \" href=\"UTD.htm?30/55/31606\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/57\">",
"     57",
"    </a>",
"    ]. Mass treatment for elimination consists of either DEC (in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/9,58-61\">",
"     9,58-61",
"    </a>",
"    ] or albendazole (400 mg) plus ivermectin (150",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83529 graphicRef83530 \" href=\"UTD.htm?21/6/21613\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/36,62,63\">",
"     36,62,63",
"    </a>",
"    ]. DEC plus albendazole is most effective in killing both microfilariae and adult female worms that produce microfilariae. However, in areas where lymphatic filariasis and onchocerciasis are both endemic, DEC plus albendazole cannot be used due to risk of severe reactions that result from rapid killing and consequent inflammatory responses to O. volvulus microfilaria in the skin and eye.",
"   </p>",
"   <p>",
"    Increasing the dosage and frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    treatment may enhance suppression of microfilariae; this was illustrated in a randomized trial including 51 W. bancrofti microfilaremic patients in Mali [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/64\">",
"     64",
"    </a>",
"    ]. Those who received twice-yearly treatment with high-dose albendazole-ivermectin therapy (800 mg and 400",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    had complete clearance of microfilaremia at 12, 18, and 24 months; those who received annual standard-dose treatment had microfilaria positive rates of 57, 32, and 28 percent, respectively. The effect did not appear to be related to greater killing of adult worms. This approach may accelerate the interruption of transmission, thereby reducing the number of years for which mass drug administration is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery depends upon the individual anatomy and local surgical expertise. Drainage of hydroceles may give some immediate relief but is almost always followed by reaccumulation of fluid. Hydrocelectomies can be helpful; among 301 patients with filariasis in Nigeria, hydrocelectomy was performed safely even in a rural area [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/65\">",
"     65",
"    </a>",
"    ]. Reconstructive surgery involving lymphatic-venous anastomoses have been attempted to improve lymphatic drainage, but the long-term benefit is still unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management of chyluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chyluria may be associated with secondary nutritional deficiency. In such cases, low-fat, high protein diets supplemented with medium-chain triglycerides can be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary infections (especially bacterial) are contributing determinants of worsening lymphedema and elephantiasis, particularly in individuals with late stage disease. Aggressive treatment of secondary infections and close attention to hygiene is critical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with lymphedema should wash affected areas twice daily, use antibacterial creams on small abrasions, keep nails clean, and wear shoes. The affected limb should be exercised regularly to promote lymph flow and should be elevated at night. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of disease control has been mass drug administration programs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/28,66,67\">",
"     28,66,67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3730852\">",
"     'Mass treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preventive measures for travelers or expatriates in endemic regions include personal protection against mosquitoes (eg, repellents and bed nets). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no vaccine available; attempts to develop effective vaccination are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15241/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3731990\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of lymphatic filariasis is based upon clinical and epidemiologic clues together with laboratory evaluation. The best laboratory tool for diagnosis of W. bancrofti infection is antigen testing; examination of blood smears is an acceptable alternative in settings where antigen testing is not available and in regions where loiasis is endemic. Diagnosis of Brugian filariasis requires blood smear examination. Ultrasound can also be a useful diagnostic tool. Eosinophilia is common and may exceed",
"      <span class=\"nowrap\">",
"       3000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wuchereria bancrofti, Brugia malayi, and Brugia timori can be differentiated from each other and from other filarial nematodes on blood smear by their morphologic characteristics (",
"      <a class=\"graphic graphic_picture graphicRef69151 \" href=\"UTD.htm?14/55/15218\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef54644 \" href=\"UTD.htm?24/52/25410\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66440 \" href=\"UTD.htm?29/27/30132\">",
"       picture 3",
"      </a>",
"      ). W. bancrofti and both Brugia species have an acellular sheath stains and is visible on light microscopy. B. malayi has terminal and subterminal nuclei in its tail; W. bancrofti has no nuclei in its tail. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Blood smears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In areas where onchocerciasis or loiasis are endemic (",
"      <a class=\"graphic graphic_figure graphicRef81417 \" href=\"UTD.htm?30/55/31606\">",
"       figure 1",
"      </a>",
"      ), evaluation for these infections should be pursued prior to treatment. Administration of diethylcarbamazine (DEC) for treatment of lymphatic filariasis in the setting of onchocerciasis or loiasis coinfection can induce an inflammatory reaction. (See",
"      <a class=\"local\" href=\"#H6728213\">",
"       'Evaluating for coinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals with microfilaremia in areas with ongoing transmission of lymphatic filariasis (but not onchocerciasis or loiasis), we suggest treatment with DEC (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is outlined above. (See",
"      <a class=\"local\" href=\"#H3730263\">",
"       'Individuals in areas with ongoing transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals with microfilaremia in areas coendemic for onchocerciasis, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg orally once daily for four to six weeks) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      orally single dose) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg orally single dose) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Issues related to treatment of loiasis infection are discussed separately. (See",
"      <a class=\"local\" href=\"#H3730493\">",
"       'Coinfection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link&amp;anchor=H14#H14\">",
"       \"Loiasis (Loa loa infection)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For individuals with microfilaremia in areas with low or no transmission, we suggest treatment with DEC (6",
"      <span class=\"nowrap\">",
"       mg/kg/d",
"      </span>",
"      orally for two weeks) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg orally once daily for four to six weeks)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      orally single dose) may be beneficial but requires further study. (See",
"      <a class=\"local\" href=\"#H3730443\">",
"       'Individuals in areas with low or no transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mass drug administration reduces the bloodborne reservoir of microfilariae to a level below that required for sustained transmission by local mosquito vectors. Mass treatment for elimination of W. bancrofti and B. malayi consists of combination therapy with any two of the following agents: DEC,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      . DEC plus albendazole is most effective in killing both microfilariae and adult female worms that produce microfilariae. However, DEC cannot be used in areas where onchocerciasis or loiasis are also endemic (",
"      <a class=\"graphic graphic_table graphicRef83529 graphicRef83530 \" href=\"UTD.htm?21/6/21613\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3730852\">",
"       'Mass treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary infections are contributing determinants of worsening lymphedema and elephantiasis, particularly in individuals with late stage disease. Aggressive treatment of secondary infections and close attention to hygiene is critical. Individuals with lymphedema should wash affected areas twice daily, use antibacterial creams on small abrasions, keep nails clean, and wear shoes. The affected limb should be exercised regularly to promote lymph flow and should be elevated at night. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/1\">",
"      Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/2\">",
"      Dissanayake S, Rocha A, Noroes J, et al. Evaluation of PCR-based methods for the diagnosis of infection in bancroftian filariasis. Trans R Soc Trop Med Hyg 2000; 94:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/3\">",
"      Lucena WA, Dhalia R, Abath FG, et al. Diagnosis of Wuchereria bancrofti infection by the polymerase chain reaction using urine and day blood samples from amicrofilaraemic patients. Trans R Soc Trop Med Hyg 1998; 92:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/4\">",
"      Ramzy RM, Farid HA, Kamal IH, et al. A polymerase chain reaction-based assay for detection of Wuchereria bancrofti in human blood and Culex pipiens. Trans R Soc Trop Med Hyg 1997; 91:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/5\">",
"      Weil GJ, Ramzy RM. Diagnostic tools for filariasis elimination programs. Trends Parasitol 2007; 23:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/6\">",
"      Chanteau S, Moulia-Pelat JP, Glaziou P, et al. Og4C3 circulating antigen: a marker of infection and adult worm burden in Wuchereria bancrofti filariasis. J Infect Dis 1994; 170:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/7\">",
"      Chandrasena TG, Premaratna R, Abeyewickrema W, de Silva NR. Evaluation of the ICT whole-blood antigen card test to detect infection due to Wuchereria bancrofti in Sri Lanka. Trans R Soc Trop Med Hyg 2002; 96:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/8\">",
"      Weil GJ, Jain DC, Santhanam S, et al. A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenemia in bancroftian filariasis. J Infect Dis 1987; 156:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/9\">",
"      Nicolas L, Plichart C, Nguyen LN, Moulia-Pelat JP. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J Infect Dis 1997; 175:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/10\">",
"      Rocha A, Addiss D, Ribeiro ME, et al. Evaluation of the Og4C3 ELISA in Wuchereria bancrofti infection: infected persons with undetectable or ultra-low microfilarial densities. Trop Med Int Health 1996; 1:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/11\">",
"      Turner P, Copeman B, Gerisi D, Speare R. A comparison of the Og4C3 antigen capture ELISA, the Knott test, an IgG4 assay and clinical signs, in the diagnosis of Bancroftian filariasis. Trop Med Parasitol 1993; 44:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/12\">",
"      Weil GJ, Lammie PJ, Richards FO Jr, Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis 1991; 164:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/13\">",
"      McCarthy JS, Guinea A, Weil GJ, Ottesen EA. Clearance of circulating filarial antigen as a measure of the macrofilaricidal activity of diethylcarbamazine in Wuchereria bancrofti infection. J Infect Dis 1995; 172:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/14\">",
"      Pani SP, Hoti SL, Vanamail P, Das LK. Comparison of an immunochromatographic card test with night blood smear examination for detection of Wuchereria bancrofti microfilaria carriers. Natl Med J India 2004; 17:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/15\">",
"      Gass K, Beau de Rochars MV, Boakye D, et al. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis 2012; 6:e1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/16\">",
"      Schuetz A, Addiss DG, Eberhard ML, Lammie PJ. Evaluation of the whole blood filariasis ICT test for short-term monitoring after antifilarial treatment. Am J Trop Med Hyg 2000; 62:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/17\">",
"      Itoh M, Weerasooriya MV, Qiu G, et al. Sensitive and specific enzyme-linked immunosorbent assay for the diagnosis of Wuchereria bancrofti infection in urine samples. Am J Trop Med Hyg 2001; 65:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/18\">",
"      Itoh M, Wu W, Sun D, et al. Confirmation of elimination of lymphatic filariasis by an IgG4 enzyme-linked immunosorbent assay with urine samples in Yongjia, Zhejiang Province and Gaoan, Jiangxi Province, People's Republic of China. Am J Trop Med Hyg 2007; 77:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/19\">",
"      Lal RB, Ottesen EA. Enhanced diagnostic specificity in human filariasis by IgG4 antibody assessment. J Infect Dis 1988; 158:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/20\">",
"      Kwan-Lim GE, Forsyth KP, Maizels RM. Filarial-specific IgG4 response correlates with active Wuchereria bancrofti infection. J Immunol 1990; 145:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/21\">",
"      Marley SE, Lammie PJ, Eberhard ML. Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. J Parasitol 1996; 82:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/22\">",
"      Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/23\">",
"      Mand S, Debrah A, Batsa L, et al. Reliable and frequent detection of adult Wuchereria bancrofti in Ghanaian women by ultrasonography. Trop Med Int Health 2004; 9:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/24\">",
"      Dreyer G, Noroes J, Amaral F, et al. Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis. Trans R Soc Trop Med Hyg 1995; 89:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/25\">",
"      Nor&otilde;es J, Dreyer G, Santos A, et al. Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivo. Trans R Soc Trop Med Hyg 1997; 91:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/26\">",
"      Freedman DO, de Almeida Filho PJ, Besh S, et al. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J Infect Dis 1994; 170:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/27\">",
"      Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/28\">",
"      Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 2005; 5:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/29\">",
"      Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/30\">",
"      Maizels RM, Bundy DA, Selkirk ME, et al. Immunological modulation and evasion by helminth parasites in human populations. Nature 1993; 365:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/31\">",
"      Hise AG, Gillette-Ferguson I, Pearlman E. The role of endosymbiotic Wolbachia bacteria in filarial disease. Cell Microbiol 2004; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/32\">",
"      Taylor MJ, Cross HF, Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 2000; 191:1429.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention - Parasites. www.cdc.gov/ncidod/dpd/professional/drgsrv_drug_table.htm (Accessed on December 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/34\">",
"      Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane Database Syst Rev 2007; :CD003758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/35\">",
"      Cao WC, Van der Ploeg CP, Plaisier AP, et al. Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment. Trop Med Int Health 1997; 2:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/36\">",
"      Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997; 350:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/37\">",
"      Shenoy RK, Kumaraswami V, Rajan K, et al. Ivermectin for the treatment of periodic malayan filariasis: a study of efficacy and side effects following a single oral dose and retreatment at six months. Ann Trop Med Parasitol 1992; 86:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/38\">",
"      Kazura JW. Ivermectin and human lymphatic filariasis. Microb Pathog 1993; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/39\">",
"      Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother 1994; 34:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/40\">",
"      Chodakewitz, J. Ivermectin and Lymphatic Filariasis: A Clinical Update. Parasitol Today 1995; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/41\">",
"      Ottesen EA, Vijayasekaran V, Kumaraswami V, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990; 322:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/42\">",
"      Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005; 365:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/43\">",
"      Klion AD, Ottesen EA, Nutman TB. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 1994; 169:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/44\">",
"      Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med 2011; 2011:175941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/45\">",
"      Stolk WA, de Vlas SJ, Habbema JD. Anti-Wolbachia treatment for lymphatic filariasis. Lancet 2005; 365:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/46\">",
"      Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/47\">",
"      Taylor MJ. Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control. Trans R Soc Trop Med Hyg 2000; 94:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/48\">",
"      Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006; 2:e92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/49\">",
"      Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health 2007; 12:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/50\">",
"      Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008; 46:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/51\">",
"      Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg 2009; 80:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/52\">",
"      Ottesen EA. Filarial infections. Infect Dis Clin North Am 1993; 7:619.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Med Lett Drug Ther, 2010.",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dpd/parasites/lymphaticfilariasis/treatment_lymphatic_filar.htm (Accessed on September 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/55\">",
"      Meyrowitsch DW, Simonsen PE, Makunde WH. Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of a low monthly dose and medicated salt. Trans R Soc Trop Med Hyg 1996; 90:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/56\">",
"      Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006; 42:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/57\">",
"      Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 2011; 86:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/58\">",
"      Bockarie MJ, Alexander ND, Hyun P, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998; 351:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/59\">",
"      Dreyer G, Addiss D, Santos A, et al. Direct assessment in vivo of the efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 1998; 92:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/60\">",
"      Moulia-Pelat JP, Glaziou P, Weil GJ, et al. Combination ivermectin plus diethylcarbamazine, a new effective tool for control of lymphatic filariasis. Trop Med Parasitol 1995; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/61\">",
"      Shenoy RK, John A, Babu BS, et al. Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. Ann Trop Med Parasitol 2000; 94:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/62\">",
"      Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998; 92:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/63\">",
"      Helmy H, Weil GJ, Ellethy AS, et al. Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans R Soc Trop Med Hyg 2006; 100:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/64\">",
"      Dembele B, Coulibaly YI, Dolo H, et al. Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. Clin Infect Dis 2010; 51:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/65\">",
"      Thomas G, Richards FO Jr, Eigege A, et al. A pilot program of mass surgery weeks for treatment of hydrocele due to lymphatic filariasis in central Nigeria. Am J Trop Med Hyg 2009; 80:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/66\">",
"      Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med 2002; 347:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/67\">",
"      World Health Organization. Global Programme to eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2006; 81:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15241/abstract/68\">",
"      Grieve RB, Wisnewski N, Frank GR, Tripp CA. Vaccine research and development for the prevention of filarial nematode infections. Pharm Biotechnol 1995; 6:737.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5680 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15241=[""].join("\n");
var outline_f14_56_15241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3731990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Blood smears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antigen tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6727038\">",
"      - Antibody tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6728213\">",
"      Evaluating for coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3729788\">",
"      - Microfilaricidal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diethylcarbamazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ivermectin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3729976\">",
"      Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3729903\">",
"      - Macrofilaricidal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730041\">",
"      Diethylcarbamazepine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730034\">",
"      Albendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730263\">",
"      Individuals in areas with ongoing transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730493\">",
"      - Coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730443\">",
"      Individuals in areas with low or no transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3730852\">",
"      Mass treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management of chyluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3731990\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5680|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/55/31606\" title=\"figure 1\">",
"      Lymphatic filariasis map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/48/31495\" title=\"figure 2\">",
"      Wuchereria life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20871\" title=\"figure 3\">",
"      Brugia life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5680|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/55/15218\" title=\"picture 1\">",
"      Wuchereria bancrofti smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/52/25410\" title=\"picture 2\">",
"      Brugia malayi smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/27/30132\" title=\"picture 3\">",
"      Brugia timori smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5680|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/23/35199\" title=\"movie 1\">",
"      Ultrasound of filarial dance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/12/12492\" title=\"table 1A\">",
"      Mass rx for lymphatic filariasis_onchocerciasis and or loiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/59/17340\" title=\"table 1B\">",
"      Rx patients with lymphatic filariasis_onchocerciasis and or loiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15242="Placement and management of indwelling ureteral stents";
var content_f14_56_15242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement and management of indwelling ureteral stents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Stephen Nakada, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Sutchin Patel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/56/15242/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/56/15242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1673162105\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral stents are one of the most common devices used by urologists. They are placed with cystoscopic guidance in an operating room setting. Ureteral stents are used to relieve ureteral obstruction, promote ureteral healing following surgery, and to assist with ureteral identification during pelvic surgery. Ureteral stent placement is associated with some degree of morbidity in the majority of patients that ranges from generalized urinary discomfort to urinary tract infection or obstruction. Much of the morbidity is related to the biocompatibility of the materials used to fashion the stent and, to some extent, their design; unfortunately, the ideal stent has yet to be discovered.",
"   </p>",
"   <p>",
"    This topic will discuss the indications for ureteral stenting, technique of ureteral stent placement, management of stents, and stent complications. The management of urinary obstruction and urinary tract infection are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162112\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR STENT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral stents are functionally used to re-establish or maintain the patency of the ureter. Ureteral stents passively dilate the ureter; urine flows through the center of the hollow stent as well as around the stent, facilitating the passage of debris [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Stent insertion initially increases ureteral peristaltic activity, but with time, the frequency and amplitude of ureteral peristalsis decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Indications for ureteral stent placement include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162119\">",
"    <span class=\"h2\">",
"     Ureteral obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral obstruction due to nephrolithiasis, tumor, or retroperitoneal fibrosis can be uncomplicated, or complicated by urinary tract infection, renal insufficiency or renal failure. Patients with complicated obstruction need prompt decompression of the urinary tract with either placement of an indwelling ureteral stent or a percutaneous nephrostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/6\">",
"     6",
"    </a>",
"    ]. Retrograde ureteral stent placement and percutaneous nephrostomy both effectively relieve obstruction and infection due to ureteral calculi. In two randomized trials comparing both treatment modalities, neither modality demonstrated superiority in promoting a more rapid recovery after drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The management of urinary tract obstruction is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A ureteral stent is generally chosen first to help relieve urinary tract obstruction because it is less invasive and has a lower risk of bleeding compared with placement of a percutaneous nephrostomy tube. However, in cases where a stent cannot be placed endoscopically or if the patient will require future percutaneous treatment of their stone burden, a percutaneous nephrostomy tube is placed primarily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162126\">",
"    <span class=\"h2\">",
"     Ureteral anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents are typically placed following the creation of a ureteral anastomosis (ie, ureteroureterostomy) to buttress the repair and ensure continued urine flow in spite of inflammation and swelling. Ureteral repair is performed for ureteral injury (eg, trauma, iatrogenic), kidney surgery (eg, pyeloplasty) or renal transplant (ie, neo-ureterostomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14866?source=see_link\">",
"     \"Overview of the surgery of deceased donor renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162133\">",
"    <span class=\"h2\">",
"     Prophylactic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic ureteral stents may be placed prior to extracorporeal shock wave lithotripsy (ESWL) if the patient has large stones (&gt;1.5 cm) to prevent ureteral obstruction, following complicated ureteroscopy due to concerns for ureteral inflammation and swelling, or prior to surgery to assist with intraoperative identification of the ureter (eg, gynecologic surgery, rectosigmoid surgery, aortoiliac surgery) which is particularly important when the operative field is scarred from previous dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of ureteral calculi\", section on 'Shock wave lithotripsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"     \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060413\">",
"    <span class=\"h1\">",
"     URETERAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ureters are bilateral tubular structures approximately 22 to 30 cm in length that are responsible for transporting urine from the renal pelvis to the bladder. The ureters begin posterior to the renal artery and course medially along the anterior surface of the psoas muscle. The gonadal vessels cross anterior to the ureter proximally and distally the ureters pass over the common iliac arteries near their bifurcation. The ureter then enters the trigone of the bladder.",
"   </p>",
"   <p>",
"    The ureter is anatomically divided into upper, middle and lower segments. The proximal ureter includes the ureter from the renal pelvis to the upper border of the sacrum. The middle ureter is that portion between the upper and lower margins of the sacrum, and the distal ureter extends from the lower border of the sacrum to the bladder. The ureter can also be divided into the abdominal and pelvic ureter, with the abdominal ureter between the renal pelvis and iliac bifurcation, and the pelvic ureter below the iliac bifurcation to the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ureteral wall is composed of several layers which include (inward to outward) an inner transitional epithelium that is in contact with urine, the lamina propria, an inner longitudinal muscle layer and an outer circular muscle layer and adventitia. The muscle layers are responsible for peristalsis. The adventitia is composed of loose connective tissue and contains blood vessels and lymphatics that traverse alongside the ureter.",
"   </p>",
"   <p>",
"    The normal ureter has three areas of narrowing that are clinically important for safe and successful ureteral endoscopy as well as stent placement. The first occurs at the ureteropelvic junction where the renal pelvis tapers into the proximal ureter. The second occurs as the ureter crosses the iliac arteries. The combination of angulation and ureteral compression are likely the cause for narrowing at this site. Lastly, the ureter is narrowed at the ureterovesical junction as it passes obliquely through an intramural tunnel of 1.5 to 2 cm in length before terminating at the ureteral orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of complete or partial duplication of the ureter can complicate ureteral stent insertion. The incidence of ureteral duplication is 1 in 125 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/16\">",
"     16",
"    </a>",
"    ]. In cases of complete duplication, it is important to understand the Weigert-Meyer rule, which states that the orifice to the lower pole ureter is more cranial and laterally positioned and the upper pole ureter is caudal and medial.",
"   </p>",
"   <p>",
"    A ureteral stent can generally be placed without manipulation of the ureteral orifice or the ureter. If anatomy is in doubt (eg, stenosis, question of duplication) a retrograde pyelogram should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162140\">",
"    <span class=\"h1\">",
"     STENT DESIGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral stents are basically hollow tubes with multiple side-holes. The proximal and distal ends are typically curled (ie, double pigtail) to limit stent migration (",
"    <a class=\"graphic graphic_picture graphicRef50265 \" href=\"UTD.htm?36/54/37742\">",
"     picture 1",
"    </a>",
"    ). A myriad of stent designs are available with variations in stent material, coating, size, and shape. The design of stents is aimed at improving patient comfort, stent handling, and reducing the incidence of urinary tract infection and encrustation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/17\">",
"     17",
"    </a>",
"    ]. The standard indwelling ureteral stent costs between $80 and $100. Most novel stents are more expensive and cost $150 or more, with cost varying depending upon the type of stent and the manufacturer. The benefit to the patient versus the cost of the stent must be considered when a novel stent is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162147\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of stent development, various materials have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Stents were initially composed of polyethylene and polyurethane, but these materials were rigid and associated with significant patient discomfort, urothelial erosion and ulceration, encrustation, and fragmentation.",
"   </p>",
"   <p>",
"    Proprietary materials that are primarily silicone-based are used in contemporary stents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/20\">",
"     20",
"    </a>",
"    ]. Silicone is inert, flexible, and elastic, and therefore one of the most tolerated biomaterials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/21\">",
"     21",
"    </a>",
"    ]. However, silicone is prone to collapse with compression, and is sometimes difficult to push into narrow or tortuous ureters. Silicone also has a low tensile strength and can snap if stretched too much.",
"   </p>",
"   <p>",
"    Biodegradable stents dissolve over time and would ideally mitigate the need for stent removal; however, incomplete stent dissolution can result in ureteral obstruction, or become a nidus for urinary tract infection or encrustation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metal stents can be used to relieve ureteral obstruction when increased radial force is needed to maintain ureteral patency, typically from tumor, which can be intrinsic causing ureteral stricture, or extrinsic causing compression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/24\">",
"     24",
"    </a>",
"    ]. Metal stents are better able to resist external compression compared with standard stents, and they generally require fewer stent changes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The use of metal stents for the treatment of benign ureteral strictures is undefined.",
"   </p>",
"   <p>",
"    Four types of metal stents have been used and include self-expanding, balloon-expandable, covered stents (eg, Resonance, also known as a coil-based stent) and thermo-expandable stents (eg, Memokath) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The self-expanding and balloon-expandable stents are short stents that are not meant to be changed or removed and are generally no longer used in the ureter. The covered metal stents (eg, Resonance) and thermo-expandable metal stents (eg, Memokath) span the entire length of the ureter and are currently in use. Thermoexpandable stents are differentiated from self-expanding stents in their ability to change conformation depending upon temperature. In addition to self-expansion, these stents can be uncoiled with the installation of cold saline (&lt;10&deg;C) making stent removal easier.",
"   </p>",
"   <p>",
"    The main benefit of metal stents in the management of malignant ureteral obstruction is a decreased morbidity associated with less frequent stent changes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/32\">",
"     32",
"    </a>",
"    ]. However, primary patency rates for metal stents are low due to hyperplastic reactions, encrustation, or tumor ingrowth, which can make these stents difficult to remove [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Patency has improved from past one-year patency rates of 17 to 30 percent to approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/24,31-35\">",
"     24,31-35",
"    </a>",
"    ]. In one retrospective review of 119 metal stents placed for malignant obstruction, 45 stents developed a hyperplastic reaction, encrustation, or tumor ingrowth requiring balloon dilation or coaxial stenting to maintain patency [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/24\">",
"     24",
"    </a>",
"    ]. Thirteen of the metal stents migrated and required repositioning. For these reasons, the authors do not use any of the metallic stents. Larger studies are needed comparing standard ureteral stents with metal stents for managing malignant ureteral obstruction to assess stent-related complications, quality of life measures, and cost.",
"   </p>",
"   <p>",
"    A novel technique to manage malignant obstruction places a standard stent parallel to the malfunctioning stent rather than exchanging the stent. In one study, the rate of subsequent malfunction was significantly decreased in the parallel stent group (29 versus 57 percent at one week, 73 versus 100 percent at three months) compared with the stent exchange group [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162154\">",
"    <span class=\"h2\">",
"     Coatings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents are typically coated with materials that are intended to improve function, improve patient tolerance and minimize the incidence of complications. Hydrogel, a coating composed of a hydrophilic polymer, traps water into its chemical structure, reducing the coefficient of friction of the stent and easing insertion and removal. The coating also decreases encrustation, improving the stent's biocompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/37\">",
"     37",
"    </a>",
"    ]. Other ureteral stent coatings, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , can be used to minimize encrustation and biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, it is unknown if these coatings reduce clinically significant catheter-associated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162290\">",
"     'Stent encrustation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162161\">",
"    <span class=\"h2\">",
"     Size/shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common ureteral stent design has both a proximal and distal curl (ie, pigtail stent) to minimize stent migration. Other types of stents include multi-length, \"non-curled\" and tail stents. Tail stents taper to a softer, smaller diameter distal loop that is designed to decrease bladder irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162239\">",
"     'Irritative symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Stent length depends upon the patient's height. A 24 or 26 cm stent is typically used in the average adult patient. Stent diameter ranges from 4 to 7 French (Fr), though the most commonly used stent diameter is 6 Fr",
"    <span class=\"nowrap\">",
"     (Fr/3",
"    </span>",
"    = diameter in millimeters). A larger diameter stent (7 Fr or 8 Fr) may be used in cases of malignant ureteral obstruction or following an endopyelotomy. Smaller diameter stents (4.7 Fr versus 6 Fr or 7 Fr) may reduce irritative symptoms, though results are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spiral stents have spiral ridges which are designed to promote urine flow around the stent. Experimental studies have shown significantly greater urine flow compared with control stents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/45\">",
"     45",
"    </a>",
"    ]. In clinical use, these stents can be difficult to deploy and may be more prone to fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162168\">",
"    <span class=\"h2\">",
"     Experimental",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal ureteral stent would be easy to insert, maintain antegrade flow of urine, maintain its position, minimize stent-related morbidity and have a low cost. Although the ideal ureteral stent does not exist, efforts to improve these characteristics are ongoing.",
"   </p>",
"   <p>",
"    Dual lumen stents improve urine flow in extrinsic ureteral obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The design for a dual lumen stent was based upon the finding that two ureteral stents placed side-by-side in a ureter with extrinsic compression led to improved urine flow; however, these stents remain experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dual durometer stents are constructed of two different materials with a more rigid proximal section to prevent migration and a softer distal end to minimize bladder irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/44\">",
"     44",
"    </a>",
"    ]. A number of dual durometer stents are available for clinical use. One trial that randomly assigned 98 patients to a conventional stent or a dual durometer stent (Polaris&trade;) did not find any significant differences in patient-reported pain or urinary stent symptom questionnaire scores [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of different pharmacological agents have also been incorporated into stent coatings to prevent encrustation, inflammation and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In an experimental rabbit urinary tract infection model, significantly decreased bacterial counts and increased survival were seen in animals that had triclosan-loaded stents (bacteriocidal) compared with control stents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/50\">",
"     50",
"    </a>",
"    ]. It is speculated that the use of drug-eluting stents may result in a lower incidence of stent-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162182\">",
"    <span class=\"h1\">",
"     STENT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral stents are generally placed by a urologist in the operating room (outpatient setting) since fluoroscopy is needed to verify accurate stent placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162190\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , antiplatelet or anticoagulation therapy does not need to be withheld prior to stent placement. A urinalysis should be obtained prior to stent placement or removal, since manipulation of the stent in the setting of a urinary tract infection can lead to bacteremia and sepsis. For patients with a positive urinalysis, urinary instrumentation should be delayed, if possible, until appropriate antibiotic treatment has sterilized the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162197\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is recommended for all procedures involving cystourethroscopy with manipulation including ureteral stent placement to minimize the potential for infection (",
"    <a class=\"graphic graphic_table graphicRef87199 \" href=\"UTD.htm?0/45/733\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Evidence supporting antibiotic prophylaxis prior to ureteral stenting is indirect; one trial specifically addresses ureteral stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Genitourinary surgery'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1673162276\">",
"     'Urinary tract infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We prefer the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing elective placement of ureteral stents should have, whenever possible, a urinalysis and urine culture, particularly if clinical symptoms suggest the presence of an active genitourinary infection. If the results are positive, the procedure should be delayed until appropriate treatment has been given, provided such a delay is feasible and appropriate.",
"     </li>",
"     <li>",
"      In general, a single dose of a fluoroquinolone given within one hour of the procedure should be sufficient. Other appropriate antibiotic choices include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , an aminoglycoside",
"      <span class=\"nowrap\">",
"       plus/minus",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , or 1st or 2nd generation cephalosporin. The antibiotic chosen should take into consideration local susceptibility patterns and any recent prior antimicrobial treatment. As an example, in communities where strains of E. coli are commonly resistant to quinolones or sulfa drugs (eg, E. coli ST121 strains or ESBL-E coli), alternative agents such as 3rd generation cephalosporins or aminoglycosides (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      or a carbapenem for ESBL-E coli) are reasonable alternatives.",
"     </li>",
"     <li>",
"      Antibiotic therapy is discontinued within 24 hours unless",
"      <strong>",
"      </strong>",
"      there is a pre-existing symptomatic urinary tract infection at the time of stent placement, in which case a therapeutic course of antibiotic therapy is given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162204\">",
"    <span class=\"h3\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a ureteral stent is a relatively safe procedure with few complications. Prior to cystoscopy and ureteral stent placement, the patient should be counseled regarding the indication for stent placement, the nature of the procedure, and possible stent-related symptoms and complications. (See",
"    <a class=\"local\" href=\"#H1673162239\">",
"     'Irritative symptoms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1673162260\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162211\">",
"    <span class=\"h2\">",
"     Stenting technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;All ureteral stents are placed and deployed in a similar manner. Simple stent placement can be performed without the need for anesthesia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    jelly is administered via the urethra to reduce the discomfort of introducing the cystoscope. Any procedure that will require ureteral manipulation or ureteral dilation is generally performed in an outpatient (or inpatient) surgical setting.",
"   </p>",
"   <p>",
"    Once the patient has been properly positioned (low dorsal lithotomy) and prepared and draped, cystourethroscopy is performed. Once the cystoscope is in the bladder, the ureteral orifice to be cannulated is identified and a guidewire is placed up the ureter into the renal pelvis under fluoroscopic guidance (",
"    <a class=\"graphic graphic_picture graphicRef58468 \" href=\"UTD.htm?10/53/11095\">",
"     picture 2",
"    </a>",
"    ). A 5 Fr access catheter is placed over the wire to the renal pelvis, the wire is removed and a nephrostogram is performed. The guidewire is replaced and the catheter removed. The ureteral stent is then placed over the wire and pushed into the ureter with a stent pusher. Markings on the stent identify the length of the stent that has passed up the ureter. Fluoroscopy can also be used to monitor stent placement. Once the proximal curl of the stent is noted to be in the renal pelvis (based upon the markings on the stent and fluoroscopy), and the end of the stent is visualized at the bladder neck, the guidewire is removed, deploying the stent.",
"   </p>",
"   <p>",
"    Correct positioning is confirmed when a full curl is visualized on fluoroscopy in the renal pelvis and in the bladder by endoscopic visualization (ie, double pigtail stent). In patients who are pregnant, ultrasound can be used to verify the position of the proximal curl, thereby avoiding radiation exposure. (See",
"    <a class=\"local\" href=\"#H1673162311\">",
"     'Ureteral stents during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060464\">",
"    <span class=\"h3\">",
"     Stent removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent removal can be performed in the office setting. After appropriate positioning, preparation, and draping, flexible cystourethroscopy is performed, and the lower pigtail of the stent is identified and grasped. For stent removal, fluoroscopy is not needed. The stent is pulled out as the cystoscope is removed. The presence of encrustation on the proximal or distal coils can complicate stent removal. (See",
"    <a class=\"local\" href=\"#H1673162290\">",
"     'Stent encrustation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1673162253\">",
"     'Stent exchange/removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162218\">",
"    <span class=\"h3\">",
"     Stent exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;For stent exchange, the distal coil of the stent is externalized outside the urethral meatus. A guidewire is placed through the stent up the ureter until a coil of the wire is seen in the renal pelvis on fluoroscopy. The previous stent is then removed and a 5 Fr ureteral access catheter placed over the wire and up the ureter. The remainder of the procedure is performed similarly to the initial stent placement. Correct placement of the stent is confirmed with fluoroscopy and cystoscope. (See",
"    <a class=\"local\" href=\"#H1673162253\">",
"     'Stent exchange/removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162225\">",
"    <span class=\"h2\">",
"     Patient instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are instructed that indwelling stents are temporary devices that need to be changed regularly and are removed when no longer needed. Longer than recommended indwelling times can lead to serious complications, including severe encrustation, urinary tract infection or obstruction and potential loss of kidney function. (See",
"    <a class=\"local\" href=\"#H1673162260\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162232\">",
"    <span class=\"h1\">",
"     ROUTINE PATIENT CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents cause symptoms in the majority of patients that include irritative voiding symptoms, suprapubic discomfort, flank pain upon voiding, and hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/9,55\">",
"     9,55",
"    </a>",
"    ]. The Ureteral Stent Symptom Questionnaire (USSQ) measures stent-related morbidity in five categories that include voiding symptoms, pain, work performance, sexual health and overall general health. Negative symptoms affecting quality of life and interfering with the ability to work are experienced by about 80 percent of stented patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study evaluated Ureteric Stent Symptoms Questionnaire (USSQ) data from 86 patients with indwelling double-J ureteral stents of different lengths and sizes that were placed for benign disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/59\">",
"     59",
"    </a>",
"    ]. Male sex, increasing body mass index (BMI), increasing stent length and a distal loop location crossing the midline were significantly associated with increasing analgesic requirements, and BMI and distal loop location were significantly associated with an increasing need for anticholinergic treatment. On multivariate analysis, the location of distal stent loop was associated with the most domains of the USSQ at 7 and 28 days after stent placement, and thus, the visualization of distal loop crossing the midline may identify patients at risk for postprocedural morbidity. When this situation is identified on cystoscopy or fluoroscopy at the time of stent placement, the stent should be repositioned. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162239\">",
"    <span class=\"h2\">",
"     Irritative symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritative symptoms are common in stented patients with the distal coil of the stent thought to be the major source of symptoms (discussed in the paragraph above). Irritation of the bladder by the stent can lead to voiding symptoms (eg, urgency, frequency), suprapubic pain, or hematuria. Stent discomfort due to bladder irritation has been treated with anticholinergic medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    ), alpha-blockers or intravesical pharmacologic therapy. Although anticholinergic medications are routinely used for the treatment of ureteral stent-related symptoms and are clinically effective, there are few formal studies. A greater number of trials are available demonstrating the efficacy of selective alpha-1 blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    ) over placebo, which is discussed in the next paragraph. One trial that compared tolterodine (anticholinergic) to alfuzosin (alpha-blocker) found similar degrees of symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, we suggest treatment of stent symptoms with anticholinergic medications or alpha-1 blockers rather than intravesical pharmacologic therapy, for which there is no convincing evidence of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/61\">",
"     61",
"    </a>",
"    ]. Alpha-1 blockade and anticholinergic agents can also be given in combination. Patients with symptoms that are refractory to treatment should have the correct positioning of the stent verified (plain abdominal film, fluoroscopy, cystoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/59,62\">",
"     59,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162211\">",
"     'Stenting technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Multiple trials have shown significant improvements in stent-related urinary symptoms with selective alpha-1 blockade (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/60,61,63-70\">",
"     60,61,63-70",
"    </a>",
"    ]. A systematic review identified 12 trials that evaluated the use of alpha blockers for the treatment of ureteral stent symptoms. A metaanalysis of four placebo-controlled trials involving 341 patients found that alpha blockers were associated with significant decreases in urinary symptoms measured using the USSQ (mean difference [MD] -6.76, 95% CI -11.52 to -2.00), and pain (MD -3.55, 95% CI -5.51 to -1.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/61\">",
"     61",
"    </a>",
"    ]. The most common adverse effects associated with alpha-blockers were dizziness, headache, hypotension, nausea, and vomiting, but discontinuation of the medication due to adverse effects was not needed. As examples, the larger trials for alfuzosin and tamsulosin are summarized briefly below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the larger trials, 100 patients were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      (10 mg by mouth once daily) or placebo for a period of four weeks following stent placement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/66\">",
"       66",
"      </a>",
"      ]. Significantly fewer patients in the alfuzosin group reported pain compared with patients who received placebo (44 versus 66 percent) and significantly better USSQ scores were also found in the alfuzosin group (22 versus 28, respectively).",
"     </li>",
"     <li>",
"      Following ureteroscopic stone removal and placement of a double-J ureteral stent, 146 patients were randomly assigned to receive placebo or 0.4 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      , once daily for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/69\">",
"       69",
"      </a>",
"      ]. Significant improvements were found in the treated group for overall pain (visual analog scale) (1.52 versus 4.01), voiding flank pain (1.93 versus 3.3), frequency (International Prostate Symptom Scale [IPSS]) (1.55 versus 3.7) and urgency (IPSS) 1.43 versus 3.82, nocturia (IPSS) (0.65 versus 2.01), and quality of life (IPSS) 1.6 versus 4.21 compared with placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another method to improve bladder-related symptoms is intravesical pharmacologic therapy; however, this approach is limited by the mode of administration. In one randomized trial, the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    were compared with a control solution following ureteral stent placement for ESWL [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/64\">",
"     64",
"    </a>",
"    ]. Of these agents, only ketorolac was found to significantly reduce flank pain at one hour postoperatively compared with the control solution.",
"   </p>",
"   <p>",
"    Changes in the design of the stent may lead to improved stent tolerance. To decrease bladder irritation, one design minimizes the amount of stent material residing within the bladder. In a comparative study, those patients stented with a smaller distal loop tail had lower pain scores and pain medication, but the result was not significant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162246\">",
"    <span class=\"h2\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sources for stent pain and discomfort include irritation of the bladder by the distal curl and flank pain upon voiding due to vesicoureteral reflux. Irritative symptoms can be managed with a combination of anticholinergic agents and alpha-1 blockade. (See",
"    <a class=\"local\" href=\"#H1673162239\">",
"     'Irritative symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Unfortunately, there is no specific treatment to prevent flank pain due to vesicoureteral reflux. Narcotic analgesics may be required and, at times, stent pain or discomfort may be so intolerable that stent removal is needed.",
"   </p>",
"   <p>",
"    For persistent flank pain, it is important to verify that the stent has not migrated or is not encrusted, causing urinary obstruction. A plain supine abdominal film (ie, KUB) can verify the placement of the stent with adequately positioned proximal and distal curls. Severe stent encrustation can be visualized as deposits on the surface of the stent. Ultrasound can be used to evaluate for hydronephrosis, indicative of significant ureteral obstruction. If the cause of the pain is found to be stent migration, encrustation or obstruction, the stent should be exchanged. (See",
"    <a class=\"local\" href=\"#H1673162283\">",
"     'Stent migration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1673162290\">",
"     'Stent encrustation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1673162218\">",
"     'Stent exchange'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162253\">",
"    <span class=\"h2\">",
"     Stent exchange/removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;We remove ureteral stents one week after initial placement to minimize the potential for infectious complications.&nbsp;For patients requiring a chronic indwelling stent, stents are usually exchanged every three months on average (some stents may be changed every 6 months, or even annually for stents made of newer materials). Chronic indwelling stents with encrustation may require more frequent exchanges. As with initial stent placement, patients found to have a positive urinalysis should be treated with antibiotics whenever possible to sterilize the urine prior to ureteral manipulation. (See",
"    <a class=\"local\" href=\"#H1673162197\">",
"     'Antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162260\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162269\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic hematuria occurs in the majority of patients with an indwelling ureteral stent, but, occasionally, gross hematuria can develop. Hematuria is due to irritation of the bladder mucosa by the stent and typically resolves following stent removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162276\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ureteral stents are prone to urinary tract infection. Prior to stent placement or stent removal, all patients should receive prophylactic antibiotics to reduce the potential for urinary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/52\">",
"     52",
"    </a>",
"    ]. When signs or symptoms of sepsis or urinary tract infection develop following stent placement, the antimicrobial agent used for treatment should not be the same as that used for antimicrobial prophylaxis. (See",
"    <a class=\"local\" href=\"#H1673162197\">",
"     'Antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As a foreign body, ureteral stents are often colonized by bacteria. Bacterial colonization of the ureteral stent occurs at approximately two weeks following stent placement, and stent colonization precedes urine colonization and urinary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/71\">",
"     71",
"    </a>",
"    ]. A short course of antibiotics (two to three days) decreases stent colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/71\">",
"     71",
"    </a>",
"    ]. However, long-term therapy does not provide an additional benefit for patients with asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early stent removal is the most important factor in preventing infectious stent complications since longer indwelling times are associated with an increasing risk for urinary tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients with diabetes mellitus and chronic renal failure are at a higher risk for urinary tract infections, and these patients should have shorter stent retention times and careful follow-up to monitor for the development of infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162232\">",
"     'Routine patient care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162283\">",
"    <span class=\"h2\">",
"     Stent migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal and distal curls of the stent are designed to minimize the likelihood of stent migration. The incidence of stent migration is about 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Inadequate stent length is the most common cause of proximal stent migration, which requires ureteroscopy to retrieve the stent. Correct positioning of an appropriately-sized stent with a full curl in the renal pelvis and bladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64090 \" href=\"UTD.htm?28/51/29490\">",
"     image 1",
"    </a>",
"    ) is the simplest measure to reduce the likelihood of stent migration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162211\">",
"     'Stenting technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recurrent symptoms in a patient treated for ureteral stricture may indicate that the stent has migrated above or below the treated stenotic region. Patients with stent migration may have symptoms of urinary obstruction (de novo or recurrent) which can present as flank pain or urinary tract infection. When stent migration is suspected, plain films of the abdomen are obtained to examine stent positioning and may demonstrate an inadequate ureteral coil either proximally or distally depending upon the direction of stent migration.",
"   </p>",
"   <p>",
"    If obstructive symptoms and urinary infection are not present, the stent can be electively removed or exchanged in the office setting. Otherwise, the patient should be treated with antibiotics and undergo urgent stent exchange.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H1673162218\">",
"     'Stent exchange'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162290\">",
"    <span class=\"h2\">",
"     Stent encrustation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of stent encrustation is not precisely known since this entity is not easily quantified and most studies evaluating it are small retrospective studies. Stent encrustation is caused by the precipitation of uric acid or calcium oxalate onto the surface of the stent (",
"    <a class=\"graphic graphic_picture graphicRef73930 \" href=\"UTD.htm?28/40/29312\">",
"     picture 3",
"    </a>",
"    ). Calcium phosphate and ammonium-magnesium-phosphate (ie, struvite) can also precipitate, but require a higher pH level which can occur in association with certain urinary tract infections (urea-splitting bacteria produce ammonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/40\">",
"     40",
"    </a>",
"    ]. Severe encrustation with stone formation can lead to urinary tract obstruction, urinary sepsis, and potential loss of kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important risk factor for stent encrustation is stent indwelling time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/40,77\">",
"     40,77",
"    </a>",
"    ]. Other factors include a history of urolithiasis, high concentration of dissolved urinary materials, type of stent material, presence of bacterial colonization, and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162253\">",
"     'Stent exchange/removal'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1673162311\">",
"     'Ureteral stents during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162297\">",
"    <span class=\"h3\">",
"     Managing the encrusted stent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encrustation that is present on the proximal and distal stent coils complicates stent removal since the coil will be resistant to straightening (",
"    <a class=\"graphic graphic_picture graphicRef73930 \" href=\"UTD.htm?28/40/29312\">",
"     picture 3",
"    </a>",
"    ). A supine abdominal film (KUB) should be obtained in patients who have had a stent in place for a prolonged period of time to identify areas of encrustation before attempted removal.",
"    <strong>",
"    </strong>",
"    If encrustation is present, stent removal should be performed under anesthesia with fluoroscopic guidance.",
"   </p>",
"   <p>",
"    Successful treatment of encrusted ureteral stents requires careful planning and a multimodal endourologic approach. Stent fragmentation can occur during the removal of these stents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/81\">",
"     81",
"    </a>",
"    ]. Any fragments that result from stent removal should be retrieved whenever possible, though some may be allowed to pass passively. If endourologic options fail to achieve stent removal, open surgery will be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To remove an encrusted stent, a rigid grasper is passed via a cystoscope and used to first break the deposits off the distal coil and then to grasp and gently pull the stent out under fluoroscopic guidance. It is important to avoid significant traction on the stent which can lead to ureteral trauma, ureteral avulsion, or stent fracture and fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/83\">",
"     83",
"    </a>",
"    ]. If the stent cannot be removed with gentle traction, a guidewire is passed through the stent to unfurl the proximal coil. Sometimes, the guidewire cannot be placed through the center of the stent due to encrustation of the lumen, or the proximal coil may not straighten. Under these circumstances, advanced interventional techniques will be needed, such as advancing a sheath over the encrusted stent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/84\">",
"     84",
"    </a>",
"    ]. When encrustation of the distal stent is associated with stone formation, cystolitholapaxy can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/83\">",
"     83",
"    </a>",
"    ]. Cystolitholapaxy refers to the use of a specialized instrument that is advanced through the cystoscope to crush the stones either mechanically or with the use of ultrasound.",
"   </p>",
"   <p>",
"    Calcification along the ureteral component of the stent can be treated with retrograde ureteroscopy and laser lithotripsy. A safety wire is passed alongside the encrusted stent to maintain ureteral access. If the ureteroscope cannot be passed easily over the wire alongside the stent, then shock wave lithotripsy is performed during a second outpatient procedure with the shocks focused on the areas of maximal encrustation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/85\">",
"     85",
"    </a>",
"    ]. Ureteroscopy is then repeated to remove the stent. In one small retrospective study, a combination of ureteroscopy and lithotripsy successfully removed encrusted stents in 86 percent of patients in an average number of 1.86 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For severe encrustation or calcification of the proximal stent, percutaneous nephrolithotomy in conjunction with antegrade ureteroscopy is preferred. The nephrolithotomy allows direct access to the renal pelvis to manage the encrusted proximal stent and ureteroscopy facilitates stent removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/83,87\">",
"     83,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162304\">",
"    <span class=\"h2\">",
"     Retained stent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained ureteral stents are generally rare and occur when a patient does not follow up for stent removal. To reduce the number of \"forgotten\" stents, a stent registry is advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/88\">",
"     88",
"    </a>",
"    ]. The use of computerized tracking significantly lowers the incidence of overdue ureteral stent exchanges. In one trial, missed stent exchanges were reduced from 12.5 to 1.2 percent over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/89\">",
"     89",
"    </a>",
"    ]. For patients with a retained stent, imaging of the stent with an abdominal plain film should be performed to determine the degree of encrustation present prior to attempted removal. (See",
"    <a class=\"local\" href=\"#H1673162290\">",
"     'Stent encrustation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162311\">",
"    <span class=\"h1\">",
"     URETERAL STENTS DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of urolithiasis during pregnancy is the same as in the general population. Treatment is generally conservative, with 70 percent of stones passing spontaneously. Percutaneous nephrostomy, ureteroscopy with lithotripsy or ureteral stent placement may be indicated if conservative management fails. The management of urolithiasis in pregnancy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"     \"Nephrolithiasis during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because radiation exposure to the fetus is a concern during pregnancy, ureteral stents can be placed with ultrasound-guidance instead of with fluoroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/90\">",
"     90",
"    </a>",
"    ]. If ultrasound is not available, pulsed fluoroscopy will minimize radiation exposure.",
"   </p>",
"   <p>",
"    Frequent stent changes, every four to six weeks, are generally needed to avoid heavy encrustation in pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. The exact cause of the increased encrustation during pregnancy is unknown, though the physiologic state of absorptive hypercalciuria and hyperuricosuria associated with pregnancy may be contributing factors. Urinary tract infections or asymptomatic bacteriuria during pregnancy may also play a causative role [",
"    <a class=\"abstract\" href=\"UTD.htm?14/56/15242/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1673162290\">",
"     'Stent encrustation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link\">",
"     \"Calcium physiology in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=see_link\">",
"     \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1673162318\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteral stents are functionally used to re-establish or maintain the patency of ureter. Ureteral stents are indicated for the management of ureteral obstruction, to protect a ureteral anastomosis prophylactically prior to extracorporeal shock wave lithotripsy (ESWL), following complicated ureteroscopy, or prior to surgery to assist with intraoperative identification of the ureter. (See",
"      <a class=\"local\" href=\"#H1673162112\">",
"       'Indications for stent placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral stents consist of hollow tubes with multiple side-holes and proximal and distal ends that are typically curled. Ureteral stents are made of silicone-based materials, though metal stents are available when increased radial force is needed (eg, malignant ureteral obstruction). A variety of coatings are also available to ease placement of stents and decrease bacterial colonization of the stent. (See",
"      <a class=\"local\" href=\"#H1673162140\">",
"       'Stent design'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral stents are generally placed by a urologist in the operating room (outpatient setting) as fluoroscopy is needed in order to verify accurate stent placement. (See",
"      <a class=\"local\" href=\"#H1673162182\">",
"       'Stent placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients undergoing elective placement of ureteral stents should have, whenever possible, a urinalysis and urine culture, particularly if clinical symptoms suggest the presence of an active genitourinary infection. Whenever possible, the procedure should be delayed until appropriate treatment has been given, provided such a delay is feasible and appropriate. (See",
"      <a class=\"local\" href=\"#H1673162197\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to ureteral stent placement, we recommend prophylactic antibiotics based upon indirect evidence supporting the use of antimicrobial prophylaxis prior to cystourethroscopy with manipulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A single dose of a fluoroquinolone given within one hour of the procedure should be sufficient. Other antibiotics may be chosen depending upon local susceptibility patterns or recent prior antimicrobial treatment. (See",
"      <a class=\"local\" href=\"#H1673162197\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureteral stents are placed, exchanged, or removed with a cystourethroscope with or without fluoroscopic guidance using endourologic techniques. Correct positioning of the stent is confirmed by the presence of a full stent coil in the renal pelvis and full stent coil in the bladder (ie, double pigtail stent). In patients who are pregnant, ultrasound can be used to verify the positioning of the proximal curl. (See",
"      <a class=\"local\" href=\"#H1673162211\">",
"       'Stenting technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1673162311\">",
"       'Ureteral stents during pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1673162218\">",
"       'Stent exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We remove ureteral stents one week after initial placement to minimize the potential for infectious complications. For patients requiring a chronic indwelling stent, stents are usually exchanged every three months on average (some stents may be changed every six months, or even annually in stents made of newer materials). Chronic indwelling stents with encrustation may require more frequent exchanges (eg, every two months). Patients who are pregnant may require stent exchange every six weeks given the higher likelihood of encrustation. (See",
"      <a class=\"local\" href=\"#H1673162218\">",
"       'Stent exchange'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1673162297\">",
"       'Managing the encrusted stent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1673162311\">",
"       'Ureteral stents during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following stent placement, patients can resume their normal activities. They are informed that irritative symptoms are common following ureteral stent placement. Irritation of the bladder from the distal stent coil can lead to voiding symptoms of urgency or frequency, suprapubic pain, or hematuria. Patients are also instructed of the importance of follow-up for stent exchanges and removal of the stent when it is no longer needed. Prolonged stent indwelling times can lead to serious complications including encrustation, urinary tract infection or urinary obstruction and potential loss of kidney function. (See",
"      <a class=\"local\" href=\"#H1673162225\">",
"       'Patient instructions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1673162260\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For irritative symptoms following ureteral stent placement, we suggest treatment with anticholinergic agents or selective alpha-1 blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      ), rather than intravesical pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Anticholinergic agents and alpha-1 blockade can also be given in combination. (See",
"      <a class=\"local\" href=\"#H1673162239\">",
"       'Irritative symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ureteral stents are prone to urinary tract infection. Bacterial colonization of the ureteral stent is common and precedes bacteriuria and infection. Longer indwelling stent duration is associated with an increasing risk for urinary tract infections. Therefore, early stent exchange or removal is important for preventing infectious complications. (See",
"      <a class=\"local\" href=\"#H1673162276\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stent migration occurs in about 4 percent of patients with ureteral stents. Presenting symptoms include pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urinary obstructive symptoms. When stent migration is suspected, plain films of the abdomen should be obtained to evaluate the position of the stent. If obstructive symptoms and urinary infection are not present, the stent can be electively removed or exchanged in the office setting. (See",
"      <a class=\"local\" href=\"#H1673162283\">",
"       'Stent migration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stent encrustation is caused by the deposition of uric acid, calcium oxalate or struvite onto the surface of the stent. Severe encrustation with stone formation can lead to urinary obstruction, urinary sepsis, and potential loss of kidney function. The most important risk factor for stent encrustation is indwelling stent duration. Other risk factors include a history of urolithiasis, high concentration of dissolved urinary materials, type of stent material, presence of bacterial colonization, and pregnancy. Encrusted stents are managed with a combination of endourologic techniques which can include cystoscopy, antegrade or retrograde ureteroscopy, cystolitholapaxy, percutaneous nephrolithotomy and laser lithotripsy. (See",
"      <a class=\"local\" href=\"#H1673162290\">",
"       'Stent encrustation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enrolling patients in a stent registry that provides reminders for stent removal is important to reduce the number of retained ureteral stents due to lost follow-up. (See",
"      <a class=\"local\" href=\"#H1673162304\">",
"       'Retained stent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/1\">",
"      Siggers JH, Waters S, Wattis J, Cummings L. Flow dynamics in a stented ureter. Math Med Biol 2009; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/2\">",
"      Ramsay JW, Payne SR, Gosling PT, et al. The effects of double J stenting on unobstructed ureters. An experimental and clinical study. Br J Urol 1985; 57:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/3\">",
"      Venkatesh R, Landman J, Minor SD, et al. Impact of a double-pigtail stent on ureteral peristalsis in the porcine model: initial studies using a novel implantable magnetic sensor. J Endourol 2005; 19:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/4\">",
"      Lennon GM, Thornhill JA, Grainger R, et al. Double pigtail ureteric stent versus percutaneous nephrostomy: effects on stone transit and ureteric motility. Eur Urol 1997; 31:24.",
"     </a>",
"    </li>",
"    <li>",
"     Waterman, BJ, Jerde, T, Nakada, SY. Ureteral physiology: implications in urological practice. AUA Update Series 2006; Vol 25, Lesson 17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/6\">",
"      Sountoulides P, Pardalidis N, Sofikitis N. Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues. J Endourol 2010; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/7\">",
"      Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol 1998; 160:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/8\">",
"      Ramsey S, Robertson A, Ablett MJ, et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol 2010; 24:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/9\">",
"      Haleblian G, Kijvikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: a systematic review. J Urol 2008; 179:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/10\">",
"      Denstedt JD, Wollin TA, Sofer M, et al. A prospective randomized controlled trial comparing nonstented versus stented ureteroscopic lithotripsy. J Urol 2001; 165:1419.",
"     </a>",
"    </li>",
"    <li>",
"     Wignall, GR, Denstedt, JD. Ureteral stents. AUA Update Series 2008; Lesson 12, Volume 27, pp102.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/12\">",
"      Preminger GM, Tiselius HG, Assimos DG, et al. 2007 guideline for the management of ureteral calculi. J Urol 2007; 178:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/13\">",
"      Chandhoke PS, Barqawi AZ, Wernecke C, Chee-Awai RA. A randomized outcomes trial of ureteral stents for extracorporeal shock wave lithotripsy of solitary kidney or proximal ureteral stones. J Urol 2002; 167:1981.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, KJ, Kabalin, JN, Cadeddu, JA. Surgical anatomy of the retroperitoneum, adrenals, kidneys and ureters. In: Campbell-Walsh Urology, 1, Wein (Ed), 2007..",
"    </li>",
"    <li>",
"     Brooks, JD. Anatomy of the lower urinary tract and male genitalia. In: Campbell-Walsh Urology, 1, Wein (Ed), 2007..",
"    </li>",
"    <li>",
"     Schlussel, RN, Retik, AB. Ectopic ureter, ureterocele, and other anomalies of the ureter. In: Campbell-Walsh Urology, 4, Wein (Ed), 2007..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/17\">",
"      Duvdevani M, Chew BH, Denstedt JD. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol 2006; 16:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/18\">",
"      Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967; 97:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/19\">",
"      Marx M, Bettmann MA, Bridge S, et al. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol 1988; 139:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/20\">",
"      Chew BH, Denstedt JD. Technology insight: Novel ureteral stent materials and designs. Nat Clin Pract Urol 2004; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/21\">",
"      Denstedt JD, Wollin TA, Reid G. Biomaterials used in urology: current issues of biocompatibility, infection, and encrustation. J Endourol 1998; 12:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/22\">",
"      Lingeman JE, Schulsinger DA, Kuo RL. Phase I trial of a temporary ureteral drainage stent. J Endourol 2003; 17:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/23\">",
"      Hadaschik BA, Paterson RF, Fazli L, et al. Investigation of a novel degradable ureteral stent in a porcine model. J Urol 2008; 180:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/24\">",
"      Liatsikos EN, Karnabatidis D, Katsanos K, et al. Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 2009; 182:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/25\">",
"      Novara G, Ficarra V, D'Elia C, et al. Prospective evaluation with standardised criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy. Eur Urol 2010; 57:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/26\">",
"      Ilie CP, Mischianu D. Editorial comment on: Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol 2010; 57:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/27\">",
"      Meria P. Editorial comment on: Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol 2010; 57:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/28\">",
"      Hendlin K, Korman E, Monga M. New metallic ureteral stents: improved tensile strength and resistance to extrinsic compression. J Endourol 2012; 26:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/29\">",
"      Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol 2011; 185:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/30\">",
"      Calleary JG. Chronic indwelling ureteral stents--what is the optimal approach? J Urol 2011; 185:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/31\">",
"      Modi AP, Ritch CR, Arend D, et al. Multicenter experience with metallic ureteral stents for malignant and chronic benign ureteral obstruction. J Endourol 2010; 24:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/32\">",
"      Sountoulides P, Kaplan A, Kaufmann OG, Sofikitis N. Current status of metal stents for managing malignant ureteric obstruction. BJU Int 2010; 105:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/33\">",
"      Pollak JS, Rosenblatt MM, Egglin TK, et al. Treatment of ureteral obstructions with the Wallstent endoprosthesis: preliminary results. J Vasc Interv Radiol 1995; 6:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/34\">",
"      Lang EK, Irwin RJ, Lopez-Martinez RA, et al. Placement of metallic stents in ureters obstructed by carcinoma of the cervix to maintain renal function in patients undergoing long-term chemotherapy. AJR Am J Roentgenol 1998; 171:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/35\">",
"      Goldsmith ZG, Wang AJ, Ba&ntilde;ez LL, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol 2012; 188:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/36\">",
"      Chen HC, Shen SH, Wang JH, et al. Parallel second stent placement for refractory ureteral stent malfunction in malignant ureteral obstruction. J Vasc Interv Radiol 2011; 22:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/37\">",
"      Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol 2003; 17:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/38\">",
"      Riedl CR, Witkowski M, Plas E, Pflueger H. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int J Antimicrob Agents 2002; 19:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/39\">",
"      Tenke P, Riedl CR, Jones GL, et al. Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. Int J Antimicrob Agents 2004; 23 Suppl 1:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/40\">",
"      Chew BH, Duvdevani M, Denstedt JD. New developments in ureteral stent design, materials and coatings. Expert Rev Med Devices 2006; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/41\">",
"      Stickler DJ. Biomaterials to prevent nosocomial infections: is silver the gold standard? Curr Opin Infect Dis 2000; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/42\">",
"      Lingeman JE, Preminger GM, Goldfischer ER, et al. Assessing the impact of ureteral stent design on patient comfort. J Urol 2009; 181:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/43\">",
"      Pilcher JM, Patel U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin Radiol 2002; 57:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/44\">",
"      Mardis HK, Kroeger RM, Morton JJ, Donovan JM. Comparative evaluation of materials used for internal ureteral stents. J Endourol 1993; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/45\">",
"      Stoller ML, Schwartz BF, Frigstad JR, et al. An in vitro assessment of the flow characteristics of spiral-ridged and smooth-walled JJ ureteric stents. BJU Int 2000; 85:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/46\">",
"      Gerber R, Nitz C, Studer UE, Danuser H. Spiral stent versus standard stent in patients with midsize renal stones treated with extracorporeal shock wave lithotripsy: which stent works better? A prospective randomized trial. J Urol 2004; 172:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/47\">",
"      Liu JS, Hrebinko RL. The use of 2 ipsilateral ureteral stents for relief of ureteral obstruction from extrinsic compression. J Urol 1998; 159:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/48\">",
"      Hafron J, Ost MC, Tan BJ, et al. Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology 2006; 68:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/49\">",
"      Davenport K, Kumar V, Collins J, et al. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J Urol 2011; 185:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/50\">",
"      Cadieux PA, Chew BH, Knudsen BE, et al. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J Urol 2006; 175:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/51\">",
"      Krambeck AE, Walsh RS, Denstedt JD, et al. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 2010; 183:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/52\">",
"      Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.",
"     </a>",
"    </li>",
"    <li>",
"     Wolf, JS, Bennett, CJ, Dmochowski, RR et al. The best practice policy statement of urologic surgery antimicrobial prophylaxis. American Urological Association, 2008. auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/antimicroprop08.pdf (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/54\">",
"      Christiano AP, Hollowell CM, Kim H, et al. Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery. Urology 2000; 55:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/55\">",
"      Erturk E, Sessions A, Joseph JV. Impact of ureteral stent diameter on symptoms and tolerability. J Endourol 2003; 17:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/56\">",
"      Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003; 169:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/57\">",
"      Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology 2002; 59:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/58\">",
"      Joshi HB, Newns N, Stainthorpe A, et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 2003; 169:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/59\">",
"      Giannarini G, Keeley FX Jr, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int 2011; 107:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/60\">",
"      Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009; 23:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/61\">",
"      Yakoubi R, Lemdani M, Monga M, et al. Is there a role for &alpha;-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011; 186:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/62\">",
"      Lee SJ, Yoo C, Oh CY, et al. Stent Position Is More Important than &alpha;-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. Korean J Urol 2010; 51:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/63\">",
"      Norris RD, Sur RL, Springhart WP, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008; 71:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/64\">",
"      Beiko DT, Watterson JD, Knudsen BE, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol 2004; 18:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/65\">",
"      Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 2009; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/66\">",
"      Deliveliotis C, Chrisofos M, Gougousis E, et al. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006; 67:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/67\">",
"      Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009; 181:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/68\">",
"      Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008; 22:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/69\">",
"      Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 2009; 83:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/70\">",
"      Nazim SM, Ather MH. Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol 2012; 26:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/71\">",
"      Paick SH, Park HK, Oh SJ, Kim HH. Characteristics of bacterial colonization and urinary tract infection after indwelling of double-J ureteral stent. Urology 2003; 62:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/72\">",
"      Kehinde EO, Rotimi VO, Al-Hunayan A, et al. Bacteriology of urinary tract infection associated with indwelling J ureteral stents. J Endourol 2004; 18:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/73\">",
"      Kehinde EO, Rotimi VO, Al-Awadi KA, et al. Factors predisposing to urinary tract infection after J ureteral stent insertion. J Urol 2002; 167:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/74\">",
"      Akay AF, Aflay U, Gedik A, et al. Risk factors for lower urinary tract infection and bacterial stent colonization in patients with a double J ureteral stent. Int Urol Nephrol 2007; 39:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/75\">",
"      Breau RH, Norman RW. Optimal prevention and management of proximal ureteral stent migration and remigration. J Urol 2001; 166:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/76\">",
"      Slaton JW, Kropp KA. Proximal ureteral stent migration: an avoidable complication? J Urol 1996; 155:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/77\">",
"      Kawahara T, Ito H, Terao H, et al. Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J Endourol 2012; 26:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/78\">",
"      Tunney MM, Keane PF, Jones DS, Gorman SP. Comparative assessment of ureteral stent biomaterial encrustation. Biomaterials 1996; 17:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/79\">",
"      Robert M, Boularan AM, El Sandid M, Grasset D. Double-J ureteric stent encrustations: clinical study on crystal formation on polyurethane stents. Urol Int 1997; 58:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/80\">",
"      Joshi H. Re: Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times. J Endourol 2012; 26:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/81\">",
"      Ringel A, Richter S, Shalev M, Nissenkorn I. Late complications of ureteral stents. Eur Urol 2000; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/82\">",
"      Singh I, Gupta NP, Hemal AK, et al. Severely encrusted polyurethane ureteral stents: management and analysis of potential risk factors. Urology 2001; 58:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/83\">",
"      Lam JS, Gupta M. Tips and tricks for the management of retained ureteral stents. J Endourol 2002; 16:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/84\">",
"      Miyaoka R, Hendlin K, Monga M. Resistance to extrinsic compression and maintenance of intraluminal flow in coil-reinforced stents (Silhouette Scaffold Device): an in vitro study. J Endourol 2010; 24:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/85\">",
"      Cass AS, Kavaney P, Levine L, et al. Extracorporeal shock wave lithotripsy for calcified ureteral stent. J Endourol 1993; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/86\">",
"      Bultitude MF, Tiptaft RC, Glass JM, Dasgupta P. Management of encrusted ureteral stents impacted in upper tract. Urology 2003; 62:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/87\">",
"      Vanderbrink BA, Rastinehad AR, Ost MC, Smith AD. Encrusted urinary stents: evaluation and endourologic management. J Endourol 2008; 22:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/88\">",
"      Lynch MF, Ghani KR, Frost I, Anson KM. Preventing the forgotten ureteral stent: implementation of a web-based stent registry with automatic recall application. Urology 2007; 70:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/89\">",
"      Ather MH, Talati J, Biyabani R. Physician responsibility for removal of implants: the case for a computerized program for tracking overdue double-J stents. Tech Urol 2000; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/90\">",
"      Jarrard DJ, Gerber GS, Lyon ES. Management of acute ureteral obstruction in pregnancy utilizing ultrasound-guided placement of ureteral stents. Urology 1993; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/91\">",
"      Borboroglu PG, Kane CJ. Current management of severely encrusted ureteral stents with a large associated stone burden. J Urol 2000; 164:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/92\">",
"      Goldfarb RA, Neerhut GJ, Lederer E. Management of acute hydronephrosis of pregnancy by ureteral stenting: risk of stone formation. J Urol 1989; 141:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/56/15242/abstract/93\">",
"      Evans HJ, Wollin TA. The management of urinary calculi in pregnancy. Curr Opin Urol 2001; 11:379.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15182 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15242=[""].join("\n");
var outline_f14_56_15242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1673162318\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162105\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162112\">",
"      INDICATIONS FOR STENT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162119\">",
"      Ureteral obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162126\">",
"      Ureteral anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162133\">",
"      Prophylactic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060413\">",
"      URETERAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162140\">",
"      STENT DESIGN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162147\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162154\">",
"      Coatings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162161\">",
"      Size/shape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162168\">",
"      Experimental",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162182\">",
"      STENT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162190\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162197\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162204\">",
"      - Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162211\">",
"      Stenting technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3060464\">",
"      - Stent removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162218\">",
"      - Stent exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162225\">",
"      Patient instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162232\">",
"      ROUTINE PATIENT CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162239\">",
"      Irritative symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162246\">",
"      Pain management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162253\">",
"      Stent exchange/removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162260\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162269\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162276\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162283\">",
"      Stent migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162290\">",
"      Stent encrustation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162297\">",
"      - Managing the encrusted stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162304\">",
"      Retained stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162311\">",
"      URETERAL STENTS DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673162318\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15182|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/51/29490\" title=\"diagnostic image 1\">",
"      Ureteral stent on plain abdominal radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15182|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/54/37742\" title=\"picture 1\">",
"      Double pigtail ureteral stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/53/11095\" title=\"picture 2\">",
"      Ureteral stent placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29312\" title=\"picture 3\">",
"      Encrusted ureteral stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/45/733\" title=\"table 1\">",
"      Antimicrobial prophylaxis for genitourinary surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=related_link\">",
"      Nephrolithiasis during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14866?source=related_link\">",
"      Overview of the surgery of deceased donor renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=related_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/40/43657?source=related_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_56_15243="Spinal cord injury grading scale";
var content_f14_56_15243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading scales for spinal cord injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        American Spinal Injury Association Scale (ASIA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        No motor or sensory function is preserved below the neurologic level through the sacral segments S4-5 (complete cord injury)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        Sensory but not motor function is preserved below the neurologic level and extends through the sacral segments S4-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Motor function is preserved below the neurologic level and the majority of key muscles below the neurologic level have a muscle grade less than 3 (ie, no antigravity movement)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        Motor function is preserved below the neurologic level and the majority of key muscles below the neurologic level have a muscle grade of at least 3 (at least antigravity movement)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        Motor and sensory functions are normal (no cord injury)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15243=[""].join("\n");
var outline_f14_56_15243=null;
var title_f14_56_15244="Rx EC pcn resistance";
var content_f14_56_15244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral therapy for enterococci with high-level ampicillin resistance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage and route",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Preferred options for monotherapy*:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vancomycin&bull;",
"      </td>",
"      <td>",
"       30 mg/kg per 24 hours in 2 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ampicillin-sulbactam&Delta;",
"      </td>",
"      <td>",
"       12 g per 24 hours in 4 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       High dose ampicillin&loz;",
"      </td>",
"      <td>",
"       18-30 g per 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       <p>",
"        Options for combination therapy:",
"       </p>",
"       <p>",
"        One of above agents",
"        <span class=\"red\">",
"         PLUS",
"        </span>",
"        one of the following (for bactericidal activity):",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gentamicin&sect;",
"      </td>",
"      <td>",
"       3 mg/kg per 24 hours in 3 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptomycin&yen;",
"      </td>",
"      <td>",
"       15 mg/kg per 24 hours in 2 equally divided doses",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Daptomycin and tigecycline are also approved for use in complicated skin and skin structure infections due to vancomycin-susceptible E faecalis; in addition tigecycline has approval for complicated intraabdominal infections associated with E. faecalis. See also Table 3: Parenteral therapy for infections due to vancomycin resistant enterococci.",
"     <br>",
"      &bull; Teicoplanin may be substituted for vancomycin where available, if MIC &le;4 mg/L. Dosing is 10 mg/kg once daily.",
"      <br>",
"       &Delta; If penicillin resistance is due to beta lactamase production, ampicillin-sulbactam may be used as the cell wall agent.",
"       <br>",
"        &loz; High dose ampicillin may be considered if MIC 16-64 mcg/mL and penicillin resistance is not due to penicillinase. See separate table for therapy of vancomycin resistant and highly ampicillin resistant E. faecium.",
"        <br>",
"         &sect; In patients with normal renal function, gentamicin dosing should be adjusted to achieve a 1-hour serum concentration of 3 mcg/mL and a trough concentration of &lt;1 mcg/mL.",
"         <br>",
"          &yen; In patients with normal renal function, streptomycin dosing should be adjusted to achieve a 1-hour serum concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15244=[""].join("\n");
var outline_f14_56_15244=null;
var title_f14_56_15245="Mycosis fungoides clinical staging";
var content_f14_56_15245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical staging system for mycosis fungoides",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        TNMB classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IA",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        or B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IB",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        or B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIA",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"        or T",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         1",
"        </sub>",
"        or N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        or B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIB",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        to N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        or B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIIA",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        to N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIIB",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        to N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVA1",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"        to T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        to N",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVA2",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"        to T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         0",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        to B",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IVB",
"       </td>",
"       <td>",
"        T",
"        <sub>",
"         1",
"        </sub>",
"        to T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        N",
"        <sub>",
"         0",
"        </sub>",
"        to N",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        M",
"        <sub>",
"         1",
"        </sub>",
"       </td>",
"       <td>",
"        B",
"        <sub>",
"         0",
"        </sub>",
"        to B",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    To be used in conjunction with the TNMB classification system for mycosis fungoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15245=[""].join("\n");
var outline_f14_56_15245=null;
var title_f14_56_15246="Family reconstruction test";
var content_f14_56_15246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DNA family reconstruction test utilizing the HLA and PCR method of testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\">",
"        Leukocyte antigens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"6\" rowspan=\"1\">",
"        HLA",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mother",
"       </td>",
"       <td>",
"        A3",
"       </td>",
"       <td>",
"        A23",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;B7",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        B44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        A2",
"       </td>",
"       <td>",
"        A3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;B7",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        B57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib mother",
"       </td>",
"       <td>",
"        A2",
"       </td>",
"       <td>",
"        A3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;B35",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        B44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 1",
"       </td>",
"       <td>",
"        A1",
"       </td>",
"       <td>",
"        A3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;B8",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        B35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 2",
"       </td>",
"       <td>",
"        A2",
"       </td>",
"       <td>",
"        A3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;B44",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        B57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PI",
"       </td>",
"       <td colspan=\"6\" rowspan=\"1\">",
"        42.81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\">",
"        DNA analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        D1S80",
"       </td>",
"       <td class=\"subtitle2\">",
"        CSFR",
"       </td>",
"       <td class=\"subtitle2\">",
"        FES",
"       </td>",
"       <td class=\"subtitle2\">",
"        VWF",
"       </td>",
"       <td class=\"subtitle2\">",
"        FGA",
"       </td>",
"       <td class=\"subtitle2\">",
"        CYP19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mother",
"       </td>",
"       <td>",
"        29, 24",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"       <td>",
"        15, 14",
"       </td>",
"       <td>",
"        7, 6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        29, 24",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        18, 14",
"       </td>",
"       <td>",
"        6, 3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sibs mother",
"       </td>",
"       <td>",
"        25, 18",
"       </td>",
"       <td>",
"        6, 7",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"       <td>",
"        18, 16",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 1",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"       <td>",
"        19, 16",
"       </td>",
"       <td>",
"        5, 4",
"       </td>",
"       <td>",
"        10, 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 2",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"       <td>",
"        19, 16",
"       </td>",
"       <td>",
"        4, 3",
"       </td>",
"       <td>",
"        10, 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PI",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        1.41",
"       </td>",
"       <td>",
"        0.94",
"       </td>",
"       <td>",
"        0.46",
"       </td>",
"       <td>",
"        1.37",
"       </td>",
"       <td>",
"        2.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\">",
"        DNA analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        ACT8P2",
"       </td>",
"       <td class=\"subtitle2\">",
"        F13B",
"       </td>",
"       <td class=\"subtitle2\">",
"        D3S1358",
"       </td>",
"       <td class=\"subtitle2\">",
"        TPOX",
"       </td>",
"       <td class=\"subtitle2\">",
"        TR",
"       </td>",
"       <td class=\"subtitle2\">",
"        D7S820",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mother",
"       </td>",
"       <td>",
"        17, 7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        16, 15",
"       </td>",
"       <td>",
"        8, 11",
"       </td>",
"       <td>",
"        6, 7",
"       </td>",
"       <td>",
"        8, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        17, 16",
"       </td>",
"       <td>",
"        10, 9",
"       </td>",
"       <td>",
"        15, 14",
"       </td>",
"       <td>",
"        8, 11",
"       </td>",
"       <td>",
"        6, 7",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sibs mother",
"       </td>",
"       <td>",
"        22, 17",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        17, 14",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7, 9.3",
"       </td>",
"       <td>",
"        10, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 1",
"       </td>",
"       <td>",
"        21, 17",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        17, 16",
"       </td>",
"       <td>",
"        8, 11",
"       </td>",
"       <td>",
"        7, 9.3",
"       </td>",
"       <td>",
"        10, 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 2",
"       </td>",
"       <td>",
"        22, 21",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        16, 14",
"       </td>",
"       <td>",
"        8, 11",
"       </td>",
"       <td>",
"        7, 9.3",
"       </td>",
"       <td>",
"        11, 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PI",
"       </td>",
"       <td>",
"        0.47",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.41",
"       </td>",
"       <td>",
"        1.19",
"       </td>",
"       <td>",
"        0.93",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\">",
"        DNA analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\">",
"        F13AO1",
"       </td>",
"       <td class=\"subtitle2\">",
"        D5S818",
"       </td>",
"       <td class=\"subtitle2\">",
"        HLADRB",
"       </td>",
"       <td class=\"subtitle2\">",
"        D18S539",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        D13S317",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mother",
"       </td>",
"       <td>",
"        7v, 7",
"       </td>",
"       <td>",
"        11, 13",
"       </td>",
"       <td>",
"        0701, 1501",
"       </td>",
"       <td>",
"        11, 12",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        11, 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child",
"       </td>",
"       <td>",
"        7v, 7",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        0701, 1501",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sibs mother",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        11, 12",
"       </td>",
"       <td>",
"        0701",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        10, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 1",
"       </td>",
"       <td>",
"        5, 7",
"       </td>",
"       <td>",
"        11, 13",
"       </td>",
"       <td>",
"        0103, 0701",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        10, 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Al. sib 2",
"       </td>",
"       <td>",
"        5, 7v",
"       </td>",
"       <td>",
"        12, 13",
"       </td>",
"       <td>",
"        0701",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        10, 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PI",
"       </td>",
"       <td>",
"        0.77",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.62",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1.35",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The PCR method of DNA testing analyzes small, common genetic sites.",
"    <div class=\"footnotes\">",
"     Combined paternity index: 1 to 1.",
"     <br>",
"      Probability of paternity: 57.20 percent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15246=[""].join("\n");
var outline_f14_56_15246=null;
var title_f14_56_15247="Assess LV volume and function 4";
var content_f14_56_15247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Accuracy of 3D LV volume measurements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation, bias and limits of agreement between 3D echocardiographic measurements of LV volumes with cardiac magnetic resonance (CMR) values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 2006; 27:460. Copyright &copy; 2006 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_56_15247=[""].join("\n");
var outline_f14_56_15247=null;
